Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2019
2019 World Conference on Lung Cancer
Access to all presentations that occur during the 2019 World Conference on Lung Cancer in Barcelona, Spain
Presentation Date(s):- Sept 7 - 10, 2019
- Total Presentations: 2848
To review abstracts of the presentations below, narrow down your search by using the Filter options below, and then select the session listing of your choice. Click the "+" for a presentation to expand & view the corresponding Abstract details.
Presentations will be available 24 hours after their live presentation time
-
+
PL01 - New Questions with Imaginative Answers
- Type: Plenary Session
- Track: Advanced NSCLC
- Presentations: 4
- Now Available
- Moderators:Enriqueta Felip
- Coordinates: 9/08/2019, 08:15 - 09:45, Barcelona (2005)
-
+
PL01.01 - Tumor-Agnostic Biologically Driven Treatments: An Endless Dream? (Now Available)
08:15 - 08:30 | Presenter: Robert C. Doebele
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
PL01.02 - The Evolution of Tissue Testing for Immunotherapy - Where Next? (Now Available)
08:30 - 08:45 | Presenter: Keith Kerr
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
PL01.03 - Will the Immunotherapy with Newer Biomarkers, Combination Therapy or New Technology Eventually Cure Lung Cancer? (Now Available)
08:45 - 09:00 | Presenter: Tetsuya Mitsudomi
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
PL01.04 - Artificial Intelligence, Big Data and Lung Cancer: Ready to Implement? (Now Available)
09:00 - 09:15 | Presenter: Hugo Aerts
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
P1.01 - Advanced NSCLC
- Type: Poster Viewing in the Exhibit Hall
- Track: Advanced NSCLC
- Presentations: 48
- Now Available
- Coordinates: 9/08/2019, 09:45 - 18:00, Exhibit Hall
-
+
P1.01-01 - Clinical Relevance of Targeting Proteins Required for Mitotic Progression to Improve Chemotherapy Response in Non-Small Cell Lung Cancer
09:45 - 09:45 | Presenter: Mark Adams
- Abstract
Loading... -
+
P1.01-02 - Pemetrexed-Carboplatin Versus Paclitaxel (Weekly)-Carboplatin as First Line Chemotherapy in Advanced Non-Squamous NSCLC (Now Available)
09:45 - 09:45 | Presenter: Prabhat Singh Malik
- Abstract
Loading... -
+
P1.01-03 - Efficacy and Safety of Biosimilar QL1101 Compared with Avastin in Patients with Non-Squamous Non-Small Cell Lung Cancer
09:45 - 09:45 | Presenter: Baohui Han
- Abstract
Loading... -
+
P1.01-04 - A Phase II Trial of Weekly Nab-Paclitaxel in the Salvage Setting for Advanced Non-Small Cell Lung Cancer: Results of NICE Salvage Study
09:45 - 09:45 | Presenter: Yoshihito Kogure
- Abstract
Loading... -
+
P1.01-05 - Phase I Study of Inhaled 5-Azacytidine (5-Aza) in Patients (Pts) with Advanced Non-Small Cell Lung Cancer (NSCLC)
09:45 - 09:45 | Presenter: Haiying Cheng
- Abstract
Loading... -
+
P1.01-06 - Comparative Effectiveness of First Line (1L) Therapies for Advanced Non-Small Cell Lung Cancer (aNSCLC): A Systematic Literature Review (SLR) (Now Available)
09:45 - 09:45 | Author(s): Sarah Goring
- Abstract
Loading... -
+
P1.01-07 - Real World Data of Docetaxel Plus Nintedanib for Pretreated NSCLC Patients: 4 Yrs Update Compassionate Use Program Single Institution in Mexico
09:45 - 09:45 | Presenter: Saul Campos-Gomez
- Abstract
Loading... -
+
P1.01-08 - Randomized Phase II Trial of CBDCA+nab-PTX vs CDDP+GEM in Patients with Chemo-Naïve Squamous Cell Lung Cancer: NJLCG1302 (Now Available)
09:45 - 09:45 | Presenter: Toshiyuki Harada
- Abstract
Loading... -
+
P1.01-09 - Randomized Trial Comparing Maintenance Pemetrexed with Observation Followed by Pemetrexed at Progression in Advanced NSCLC (Now Available)
09:45 - 09:45 | Presenter: Kristin Stokke
- Abstract
Loading... -
+
P1.01-10 - Impact of Anti-COPD Support Treatment in Advanced NSCLC Patients with COPD Undergoing Chemotherapy as First-Line Treatment
09:45 - 09:45 | Presenter: Fei Wang
- Abstract
Loading... -
+
P1.01-11 - Quality of Life in NSCLC Patients Treated with Docetaxel and Either Plinabulin or Pegfilgrastim for Prevention of Neutropenia (Now Available)
09:45 - 09:45 | Presenter: Douglas Blayney
- Abstract
Loading... -
+
P1.01-12 - Trends in the National Cancer Institute (NCI) Sponsored Lung Cancer Clinical Trials Pre and Post NCI’s National Clinical Trials Network (NCTN)
09:45 - 09:45 | Presenter: Shakun Malik
- Abstract
Loading... -
+
P1.01-13 - Efficacy and Safety of Concurrent Anti-Tuberculosis Treatment and Chemotherapy in Lung Cancer Patients with Co-Existent Tuberculosis
09:45 - 09:45 | Author(s): Meifeng Ye
- Abstract
Loading... -
+
P1.01-14 - The Impact of Systemic Treatment on Brain Metastasis in Patients with Non-Small-Cell Lung Cancer: A Nationwide Population-Based Cohort Study
09:45 - 09:45 | Presenter: Yoon Ho Ko
- Abstract
Loading... -
+
P1.01-15 - Multicenter, Single-Arm Phase II Study of Nab-Paclitaxel/Carboplatin in Untreated PS2 Patients with Advanced NSCLC: TORG1426 (Now Available)
09:45 - 09:45 | Presenter: Katsuhiko Naoki
- Abstract
Loading... -
+
P1.01-16 - Evolution of Systemic Therapy Uptake in NSCLC Over Time: The Impact of New Therapies
09:45 - 09:45 | Presenter: Paul Wheatley-Price
- Abstract
Loading... -
+
P1.01-17 - Changes in Pulmonary Function During Platinum-Doublet Chemotherapy for Lung Cancer
09:45 - 09:45 | Presenter: Jeremias Götschke
- Abstract
Loading... -
+
P1.01-18 - Integrated Genomic and DNA Methylation Analyses of Non-Small Cell Lung Cancer Patients with Brain Metastases
09:45 - 09:45 | Presenter: Yun Fan
- Abstract
Loading... -
+
P1.01-19 - Predictive and Prognostic Values of ctDNA Clearance in Osimertinib Treated Advanced Non-Small Cell Lung Cancer Cohort (Now Available)
09:45 - 09:45 | Presenter: Yong Song
- Abstract
Loading... -
+
P1.01-20 - The Association Between BRAF Mutation Class and Clinical Features in BRAF-Mutant Chinese Non-Small Cell Lung Cancer Patients
09:45 - 09:45 | Presenter: Quan Lin
- Abstract
Loading... -
+
P1.01-21 - Sputum Can Serve as an Alternative Source for Liquid Biopsy in Patients with Lung Cancer (Now Available)
09:45 - 09:45 | Presenter: Ling Qin
- Abstract
Loading... -
+
P1.01-22 - Investigation of Acquired Resistance for EGFR-TKI Plus Bevacizumab as 1st Line Treatment in Patients with EGFR Sensitive Mutant NSCLC
09:45 - 09:45 | Presenter: Yongchang Zhang
- Abstract
Loading... -
+
P1.01-23 - Retrospective Analysis of Real-World Clinico-Genomic Data for Clinical Impact of Genomic Profiling of ctDNA in NSCLC
09:45 - 09:45 | Presenter: Russell Madison
- Abstract
Loading... -
+
P1.01-24 - Preclinical Proteomic Evaluation of Alternating ALK TKI Therapy Versus Continuous Dosing in ALK NSCLC to Inform the ALKternate Clinical Trial
09:45 - 09:45 | Presenter: Malinda Itchins
- Abstract
Loading... -
+
P1.01-25 - Real-World Outcomes of Advanced NSCLC Patients with Common and Uncommon/Complex EGFR Mutation Profiles
09:45 - 09:45 | Presenter: Gregory J Riely
- Abstract
Loading... -
+
P1.01-26 - TP53 Mutations in EGFR mt+ NSCLC IV: Strong Independent Predictive Factor for ORR, PFS and OS Irrespective of T790M (Now Available)
09:45 - 09:45 | Presenter: Julia Roeper
- Abstract
Loading... -
+
P1.01-27 - Serial Circulating Tumor DNA (ctDNA) Analysis of Blood and Saliva Predicts Osimertinib Response and Resistance in EGFR-Mutant NSCLC
09:45 - 09:45 | Presenter: Chul Kim
- Abstract
Loading... -
+
P1.01-28 - Mutational Heterogeneity Between Primary Pulmonary Cancer Lesions and Matched Brain Metastases (Now Available)
09:45 - 09:45 | Presenter: Linlin link Li
- Abstract
Loading... -
+
P1.01-29 - MLPH Promotes Epithelial–Mesenchymal Transition and Brain Metastasis via Cdc42/PAK1 Signaling in Non-Small Cell Lung Cancer (Now Available)
09:45 - 09:45 | Author(s): Chunhua Wei
- Abstract
Loading... -
+
P1.01-30 - Non-Small Cell Lung Cancer (NSCLC) Next Generation Sequencing (NGS): Integrating Genomic Sequencing into a Publicly Funded Health Care Model (Now Available)
09:45 - 09:45 | Author(s): Kirstin Perdrizet
- Abstract
Loading... -
+
P1.01-31 - Evaluating Engineered Heme-Sequestering Peptides for Treating Non-Small Cell Lung Cancer Orthotopic Tumor Model Using Multi-Modality Imaging
09:45 - 09:45 | Author(s): Shigen Zhong
- Abstract
Loading... -
+
P1.01-32 - Bronchoalveolar Lavage as an Alternative to Rebiopsy for Detection of T790M Mutation in NSCLC Patients with Acquired Resistance to EGFR-TKIs
09:45 - 09:45 | Presenter: Heejoung Kim
- Abstract
Loading... -
+
P1.01-33 - Genetic Variants in FIG4 and IGF1R in the Endosome-Related Genes Are Associated with Non-Small Cell Lung Cancer Survival
09:45 - 09:45 | Author(s): Sen Yang
- Abstract
Loading... -
+
P1.01-34 - Early Assessment of Therapy Response in Non-Small Cell Lung Cancer (NSCLC) via Longitudinal ctDNA Analysis
09:45 - 09:45 | Presenter: Stephanie Yaung
- Abstract
Loading... -
+
P1.01-35 - Real World Characterization of Advanced Non-Small Cell Lung Cancer in Never Smokers (Now Available)
09:45 - 09:45 | Presenter: Katie Kerrigan
- Abstract
Loading... -
+
P1.01-36 - Clinical Potential of Tissue Tumor Mutational Burden (tTMB) and Blood TMB (bTMB) as a Biomarker in Non-Small Cell Lung Cancer
09:45 - 09:45 | Presenter: Jianying Zhou
- Abstract
Loading... -
+
P1.01-37 - Radiotherapy Changed the Subclonal Composition of Brain Metastasis from Non Small Cell Lung Cancer: NGS-Based Analysis of Cerebrospinal Fluid
09:45 - 09:45 | Presenter: Xiaoxia Zhu
- Abstract
Loading... -
+
P1.01-38 - Clinical Significance According to EGFR Mutation Subtypes in Lung Adenocarcinoma: Korean Multicenter Experience
09:45 - 09:45 | Presenter: Jung Hyun Chang
- Abstract
Loading... -
+
P1.01-39 - Is There an Association Between Intracranial Progression and Overall Survival or Neurologic Death in Patients with EGFR Positive NSCLC?
09:45 - 09:45 | Presenter: Mark Doherty
- Abstract
Loading... -
+
P1.01-40 - EGFR ctDNA Detection: The Impact of Site of Progression and Burden of Progressive Disease
09:45 - 09:45 | Presenter: Alexandra Pender
- Abstract
Loading... -
+
P1.01-41 - Involvement of the JNK Pathway in Bruceine D-Induced Apoptosis in Human Non-Small Cell Lung Cancer Cells (Now Available)
09:45 - 09:45 | Presenter: Bi qin Tan
- Abstract
Loading... -
+
P1.01-42 - Whole-Exome Sequencing Identifies Novel Somatic Mutations Associated with Prognosis in Lung Cancer Metastatic to the Brain
09:45 - 09:45 | Presenter: Chunxia Su
- Abstract
Loading... -
+
P1.01-43 - Programmed-Death Ligand 1 Spectrum in a Large Cohort of Genetically Characterized Non-Small Cell Lung Cancer Patients
09:45 - 09:45 | Presenter: Elba Marin
- Abstract
Loading... -
+
P1.01-44 - The Role of Microbiota on the Development of Non-Small-Cell Lung Cancer (Now Available)
09:45 - 09:45 | Author(s): Hui Lu
- Abstract
Loading... -
+
P1.01-45 - A NGS-Based ctDNA Test to Monitor Disease Progression and Treatment Response in Advanced Stage Non-Small Cell Lung Cancer
09:45 - 09:45 | Presenter: Jin Jen
- Abstract
Loading... -
+
P1.01-46 - Response Assessment Using Plasma Cell-Free DNA (cfDNA) – When Is the Optimal Time to Assess Response?
09:45 - 09:45 | Presenter: Michael L Cheng
- Abstract
Loading... -
+
P1.01-47 - Prospective Study for Usefulness of Plasma DNA on Prediction of Third Generation EGFR Tyrosine Kinase Inhibitors (S-PLAT Study) (Now Available)
09:45 - 09:45 | Presenter: Chiho Nakashima
- Abstract
Loading... -
+
P1.01-48 - EGFR Testing in England – Real World Evidence from the National Lung Cancer Audit (NLCA) Spotlight on Molecular Testing (Now Available)
09:45 - 09:45 | Author(s): Judith Tweedie
- Abstract
Loading... -
+
P1.01-49 - Serial Changes in Whole-Genome Cell-Free DNA (cfDNA) to Identify Disease Progression Prior to Imaging in Advanced NSCLC
09:45 - 09:45 | Author(s): Andrew A. Davis
- Abstract
Loading... -
+
P1.01-50 - Impact of Concomitant HER2 Alterations in Mediating Clinical Outcomes of EGFR-Mutant Patients to Different Generation of EGFR-TKIs (Now Available)
09:45 - 09:45 | Presenter: Ying Cheng
- Abstract
Loading... -
+
P1.01-51 - Micropapillary Predominant and Pathologic Stage Were Risk Factors for Postoperative Brain Metastasis in Lung Adenocarcinoma (Now Available)
09:45 - 09:45 | Presenter: Takao Shigenobu
- Abstract
Loading... -
+
P1.01-52 - Cell-Free Tumor DNA (ctDNA) Utility in Detection of Original Sensitizing and Resistant EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC) (Now Available)
09:45 - 09:45 | Presenter: Jason Scott Agulnik
- Abstract
Loading... -
+
P1.01-53 - Clinical Utility of Two Different Plasma-Based EGFR Mutation Tests in Patients with Advanced Non-Small Cell Lung Cancer
09:45 - 09:45 | Presenter: Yun-Gyoo Lee
- Abstract
Loading... -
+
P1.01-54 - Somatic Genome Alterations in Lung Cancer Patients Diagnosed with Li Fraumeni Syndrome (Now Available)
09:45 - 09:45 | Presenter: Maria Jove
- Abstract
Loading... -
+
P1.01-55 - Updated Analysis of Outcomes by Histology vs Cytology PD-L1 22C3 Antibody Testing in Advanced Non-Small Cell Lung Cancer
09:45 - 09:45 | Presenter: Arani Sathiyapalan
- Abstract
Loading... -
+
P1.01-56 - Increased ROS1 and RET Transcripts in Fusion-Negative NSCLC Patients
09:45 - 09:45 | Author(s): Cristina Aguado
- Abstract
Loading... -
+
P1.01-57 - Association of Initial PD-L1 Expression with T790M-Acquired Resistance in Advanced EGFR-Mutant Lung Adenocarcinoma Patients (Now Available)
09:45 - 09:45 | Presenter: Kazumi Nishino
- Abstract
Loading... -
+
P1.01-58 - Comprehensive Serial Biomaterial Acquisition in Advanced NSCLC: Feasibility, Challenges and Perspectives
09:45 - 09:45 | Author(s): Sabine Wessels
- Abstract
Loading... -
+
P1.01-59 - Expanding Access to Large-Scale Genomic Mutational Analyses for Patients with Advanced NSCLC in Italy
09:45 - 09:45 | Presenter: Vanesa Gregorc
- Abstract
Loading... -
+
P1.01-60 - Prognostic Impact of PD-L1 Expression on EGFR Tyrosine Kinase Inhibition in Lung Adenocarcinoma
09:45 - 09:45 | Presenter: Minsu Kang
- Abstract
Loading... -
+
P1.01-61 - A Phase II Umbrella Study of Camrelizumab in Different PD-L1 Expression Cohorts in Pre-Treated Advanced/Metastatic Non-Small Cell Lung Cancer
09:45 - 09:45 | Presenter: Yi-Long Wu
- Abstract
Loading... -
+
P1.01-62 - Association of Baseline Pulmonary Fibrosis with the Outcome of PD-1 Inhibitor in Patients with Advanced Non-Small Cell Lung Cancer
09:45 - 09:45 | Presenter: Shiqi Mao
- Abstract
Loading... -
+
P1.01-63 - Impact of Prior Radiation Pneumonitis on Incidence of Immunotherapy Related Pneumonitis
09:45 - 09:45 | Author(s): Melanie Wain Kier
- Abstract
Loading... -
+
P1.01-64 - Predictive Value of K-Ras Subset Mutations and PD-L1 in Pulmonary Sarcomatoid Carcinoma (PSC) (Now Available)
09:45 - 09:45 | Author(s): ihab Eldessouki
- Abstract
Loading... -
+
P1.01-65 - Immune Gene Expression, Bayesian Network and Genetic Mutation Analysis in Advanced NSCLC Patients Treated with Immunotherapy (Now Available)
09:45 - 09:45 | Author(s): Sara Baglivo
- Abstract
Loading... -
+
P1.01-66 - A CT-Based Radiomics Approach to Predict PD1 Inhibitor Response in Non-Small-Cell Lung Cancer (Now Available)
09:45 - 09:45 | Presenter: Jialei Wang
- Abstract
Loading... -
+
P1.01-67 - Ph I/II Carboplatin, Nab-Paclitaxel and Pembrolizumab for Advanced NSCLC (HCRN LUN13-175): Outcomes by Nab-Paclitaxel Dose
09:45 - 09:45 | Presenter: Ryan D Gentzler
- Abstract
Loading... -
+
P1.01-68 - Monitoring Clinical Responses Measuring PD-L1 in cfRNA in Plasma of Non-Small Cell Lung Cancer Patients Undergoing Systemic Therapy (Now Available)
09:45 - 09:45 | Presenter: Luis Raez
- Abstract
Loading... -
+
P1.01-69 - Blood Serum Amyloid A as Potential Predictor of Response to First-Line Pembrolizumab in Patients with Advanced Non-Small-Cell Lung Cancer
09:45 - 09:45 | Presenter: Vincenzo Di Noia
- Abstract
Loading... -
+
P1.01-70 - Dominant Circulating Myeloid Populations Are Associated with Poor Response in NSCLC Treated with 1st Line PD-1 Monotherapy (Now Available)
09:45 - 09:45 | Presenter: Sally CM Lau
- Abstract
Loading... -
+
P1.01-71 - Bone Metastases and Skeletal-Related Events in Patients with Metastatic NSCLC Treated with ICIs: A Multi-Institutional Study (Now Available)
09:45 - 09:45 | Presenter: Angel Qin
- Abstract
Loading... -
+
P1.01-72 - A Phase II Study of Selective AXL Inhibitor Bemcentinib and Pembrolizumab in Patients with NSCLC Refractory to Anti-PD(L)1
09:45 - 09:45 | Presenter: Matthew Krebs
- Abstract
Loading... -
+
P1.01-73 - An Explorative Analysis of Pemetrexed +/- Pembrolizumab Maintenance from KEYNOTE-189 Versus PARAMOUNT, PRONOUNCE, and JVBL
09:45 - 09:45 | Presenter: Edward Garon
- Abstract
Loading... -
+
P1.01-74 - A Retrospective Study Evaluating Clinical Predictors of Duration of Response to Immune Checkpoint Inhibitors in Advanced NSCLC (Now Available)
09:45 - 09:45 | Presenter: Yahya Ibrahim
- Abstract
Loading... -
+
P1.01-75 - Prognostic Impact of Neutrophil-to-Lymphocyte Ratio (NLR) for Advanced Non-Small Cell Lung Cancer
09:45 - 09:45 | Presenter: Masashi Ishihara
- Abstract
Loading... -
+
P1.01-76 - Randomized Phase II Study of Immunotherapy With or Without Low Dose Chemotherapy for Patients with Performance Status of 2
09:45 - 09:45 | Author(s): Tamjeed Ahmed
- Abstract
Loading... -
+
P1.01-77 - Impact of Oral Drugs on the Prognosis of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab
09:45 - 09:45 | Presenter: Yoshihiko Taniguchi
- Abstract
Loading... -
+
P1.01-78 - Treatment-Related Adverse Events in Patients with Advanced NSCLC Treated with First-Line Atezolizumab Chemoimmunotherapy (Now Available)
09:45 - 09:45 | Author(s): Sriman Swarup
- Abstract
Loading... -
+
P1.01-79 - G8 Screening Scores in Elderly Advanced Lung Cancer Patients: A Prospective Single Institution Study (Now Available)
09:45 - 09:45 | Presenter: Xiaorong Wu
- Abstract
Loading... -
+
P1.01-80 - Lung Cancer Prognostic Index Performance in US Real-World Advanced Non-Small Cell Lung Cancer Patients
09:45 - 09:45 | Presenter: Roma Shah
- Abstract
Loading... -
+
P1.01-81 - A New Prognostic Index Combines the Metabolic Response and RECIST 1.1 to Evaluate the Therapeutic Response in Patients with Lung Cancer
09:45 - 09:45 | Presenter: Wenfang Tang
- Abstract
Loading... -
+
P1.01-82 - The Different Frequencies and Genetic Profiles of Histologic Transformation After Different EGFR-TKIs in EGFR-Mutant Adenocarcinomas
09:45 - 09:45 | Presenter: Jin Kang
- Abstract
Loading... -
+
P1.01-83 - Comparative Efficacy Analysis Between Entrectinib Trial and Crizotinib Real-World ROS1 Fusion-Positive (ROS1+) NSCLC Patients
09:45 - 09:45 | Presenter: Robert C. Doebele
- Abstract
Loading... -
+
P1.01-84 - Interaction of Lorlatinib with CYP2B6, CYP2C9, UGT, and P-gp Probe Drugs in Patients with Advanced Non-Small Cell Lung Cancer
09:45 - 09:45 | Presenter: Joseph Chen
- Abstract
Loading... -
+
P1.01-85 - Treatment for Advanced NSCLC with EGFR Mutations and De Novo MET Amplification/Overexpression
09:45 - 09:45 | Presenter: Han-Min Wang
- Abstract
Loading... -
+
P1.01-86 - Occurrence of de Novo Dual HER2/HER3 or HER2/EGFR TMD Mutations: Extending the Spectrum of Targetable Mono-HER2 TMD in NSCLC?
09:45 - 09:45 | Presenter: Sai-Hong Ignatius Ou
- Abstract
Loading... -
+
P1.01-87 - Acquired Resistance Mechanisms and Clinical Outcomes for Patients with Epidermal Growth Factor Receptor (EGFR) Positive Non-Small Cell Lung Cancer (NSCLC) Treated with Osimertinib (Now Available)
09:45 - 09:45 | Presenter: Tejas Patil
- Abstract
Loading... -
+
P1.01-88 - PS 2 Patients with Advanced EGFR Mutant NSCLC: Subset Analysis of a Phase III Randomized Trial Comparing Gefitinib to Gefitinib with Chemotherapy
09:45 - 09:45 | Presenter: Kumar Prabhash
- Abstract
Loading... -
+
P1.01-89 - A Multicenter Phase 1/2a Trial of CLN-081 in NSCLC with EGFR Exon 20 Insertion Mutations
09:45 - 09:45 | Presenter: Zofia Piotrowska
- Abstract
Loading... -
+
P1.01-90 - Update Phase II Results of Early Primary Tumor Stereotactic Body Radiotherapy Combined with First-Line EGFR-TKI in Advanced EGFR Mutated NSCLC (Now Available)
09:45 - 09:45 | Presenter: Dongqing Lv
- Abstract
Loading... -
+
P1.01-91 - Clinical Outcomes of Various Resistance Mechanisms of Osimertinib in Chinese Advanced Non-Small Cell Lung Cancer Patients (Now Available)
09:45 - 09:45 | Presenter: Puyuan Xing
- Abstract
Loading... -
+
P1.01-92 - Underlying Mechanisms That Potentially Affect Prognosis to EGFR-TKI in EGFR-Positive Patients with Non-Small Cell Lung Cancer (Now Available)
09:45 - 09:45 | Presenter: Ying Cheng
- Abstract
Loading... -
+
P1.01-93 - Metastases Sites as a Prognostic Factor in a Real-World Multicenter Cohort Study of Spanish ALK-Positive NSCLC Patients (p)
09:45 - 09:45 | Presenter: Laura Angelats
- Abstract
Loading... -
+
P1.01-94 - JNJ-61186372, an EGFR-cMet Bispecific Antibody, in EGFR Exon 20 Insertion-Driven Advanced NSCLC
09:45 - 09:45 | Author(s): Jiyeon Yun
- Abstract
Loading... -
+
P1.01-95 - Efficacy and Safety of Anlotinib in Combination with Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
09:45 - 09:45 | Author(s): Baohui Han
- Abstract
Loading... -
+
P1.01-96 - US Real-World Management of EGFR-Mutated Advanced NSCLC: Survival After First-Line EGFR-Tyrosine Kinase Inhibitor Treatment
09:45 - 09:45 | Presenter: Jorge Nieva
- Abstract
Loading... -
+
P1.01-97 - Modified RANO-LM Criteria to Evaluate the Radiological Response of Osimertinib in EGFR T790M Positive NSCLC with Leptomeningeal Metastases
09:45 - 09:45 | Author(s): Minjung Seong
- Abstract
Loading... -
+
P1.01-98 - Outcomes in Advanced NSCLC Patients Treated with 1st Line EGFR-TKI Based on Mutation Detection from Tissue or cfDNA-Based Genomic Sequencing
09:45 - 09:45 | Presenter: Hai Tran
- Abstract
Loading... -
+
P1.01-99 - EGFR-Wild Type Patients Responding to TKI: Revisiting Pathology with Newer Technology (Now Available)
09:45 - 09:45 | Author(s): Andreas Papadakis
- Abstract
Loading... -
+
P1.01-100 - Effect of Osimertinib in Non-Small Cell Lung Cancer Patients with Brain Metastases After Progression Following Front-Line EGFR-TKI Therapy (Now Available)
09:45 - 09:45 | Author(s): Xiaoqing Yu
- Abstract
Loading... -
+
P1.01-101 - Efficacy of Immune Checkpoint Inhibition in RET Fusion Positive Non-Small Cell Lung Cancer Patients
09:45 - 09:45 | Presenter: Anthony N Sireci
- Abstract
Loading... -
+
P1.01-102 - Actionable Gene Aberration and the Response of Matched Therapy Among Patients with Non-Small-Cell Lung Carcinoma (Now Available)
09:45 - 09:45 | Presenter: Takaaki Mizuno
- Abstract
Loading... -
+
P1.01-103 - Preliminary Results of Brigatinib in Japanese Patients (Pts) Who Previously Received Alectinib: Brigatinib-2001 Study
09:45 - 09:45 | Presenter: Shuji Murakami
- Abstract
Loading... -
+
P1.01-104 - Survivals in ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer Treated with First-Line Crizotinib
09:45 - 09:45 | Presenter: Yu-Er Gao
- Abstract
Loading... -
+
P1.01-105 - US Real-World Management of EGFR-Mutated Advanced NSCLC: Prescribing and Attrition Data from First-To-Second-Line Treatment (Now Available)
09:45 - 09:45 | Presenter: Karen L Reckamp
- Abstract
Loading... -
+
P1.01-106 - Clinical Features and Tumor Immune Microenvironment Related to Acquired Resistance to EGFR-TKI in NSCLC Patients with EGFR Mutation
09:45 - 09:45 | Presenter: Pei Zhang
- Abstract
Loading... -
+
P1.01-107 - KEYNOTE-495/KeyImPaCT: Phase 2 Biomarker-Directed Study of Pembrolizumab-Based Therapy for Non–Small Cell Lung Cancer
09:45 - 09:45 | Presenter: Martin Gutierrez
- Abstract
Loading... -
+
P1.01-108 - PACIFIC-6: A Phase II Study of Durvalumab Following Sequential Chemoradiotherapy in Patients with Stage III, Unresectable NSCLC
09:45 - 09:45 | Presenter: Marina Chiara Garassino
- Abstract
Loading... -
+
P1.01-109 - Phase II Trial of Pemetrexed/Carboplatin/Bevacizumab +/- Atezolizumab in NSCLC Patients That Are EGFR Mutated or Never Smoked (Now Available)
09:45 - 09:45 | Presenter: J. Nicholas Bodor
- Abstract
Loading... -
+
P1.01-110 - Novel Regimens Versus Standard-of-Care in NSCLC: A Phase II, Randomized, Open-Label, Platform Trial Using a Master Protocol (Now Available)
09:45 - 09:45 | Presenter: David R Spigel
- Abstract
Loading... -
+
P1.01-111 - ATEZO-BRAIN, A Single-Arm Phase II Study of Atezolizumab Combined with Chemotherapy in Stage IV NSCLC Patients with Untreated Brain Metastases
09:45 - 09:45 | Presenter: Ernest Nadal
- Abstract
Loading... -
+
P1.01-112 - Phase 3, Randomized, Double-Blind Trial of First-Line Pembrolizumab With or Without Lenvatinib in Metastatic NSCLC: LEAP-007
09:45 - 09:45 | Presenter: Tarek Mekhail
- Abstract
Loading... -
+
P1.01-113 - Phase 1b Trial of Cabozantinib or Cabozantinib Plus Atezolizumab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
09:45 - 09:45 | Presenter: Farah Louise Lim
- Abstract
Loading... -
+
P1.01-114 - A Phase 2 Study of MLN4924 (Pevonedistat) in Combination with Carboplatin and Paclitaxel in Advanced NSCLC Previously Treated with Immunotherapy
09:45 - 09:45 | Presenter: Ticiana A. Leal
- Abstract
Loading... -
+
P1.01-115 - Long-Term Effects of Concurrent Chemoradiotherapy on Quality of Life in Locally Advanced Non-Small Cell Lung Cancer Patients
09:45 - 09:45 | Author(s): Iris Walraven
- Abstract
Loading... -
+
P1.01-116 - Early Immune-Related Adverse Events Under PD-1/PD-L1 Inhibitors Predict Better Progression-Free Survival in NSCLC
09:45 - 09:45 | Presenter: Maxime Boussageon
- Abstract
Loading... -
+
P1.01-117 - Pulmonary Function Monitoring in Patients with Oligometastatic NSCLC Who Receive Stereotactic Body Radiation Therapy
09:45 - 09:45 | Presenter: Marisol Arroyo-Hernandez
- Abstract
Loading... -
+
P1.01-118 - Overall Survival in Pts with EGFRm+ NSCLC Receiving Sequential Afatinib and Osimertinib: Updated Analysis of the GioTag Study
09:45 - 09:45 | Presenter: Maximilian J. Hochmair
- Abstract
Loading... -
+
P1.01-119 - Modified Lung Immune Prognostic Index (mLIPI) as a Predictive Tool of Nivolumab Outcomes in Advanced NSCLC Patients
09:45 - 09:45 | Presenter: Rebecca Jane Moor
- Abstract
Loading... -
+
P1.01-120 - Immune Checkpoint Inhibitors Versus Second Line Chemotherapy for Patients with Lung Cancer Refractory to First Line Chemotherapy (Now Available)
09:45 - 09:45 | Presenter: Corentin Lefebvre
- Abstract
Loading... -
+
P1.01-121 - Superior Outcomes of 1st Line EGFR TKI in Next-Generation Sequencing Identified Uncommon EGFR Exon 19delins Mutation Non-Small Cell Lung Cancer
09:45 - 09:45 | Presenter: Yongchang Zhang
- Abstract
Loading... -
+
P1.01-122 - A Clinical Utility Study of Plasma DNA Next Generation Sequencing Guided Treatment of Uncommon Drivers in Advanced Non-Small-Cell Lung Cancers
09:45 - 09:45 | Presenter: Hai-yan Tu
- Abstract
Loading... -
+
P1.01-123 - Recent Clinical Outcomes of Upfront Surgery Followed by Adjuvant Therapy for Resectable Pathological N2 Non-Small Cell Lung Cancer
09:45 - 09:45 | Presenter: Jae Kwang Yun
- Abstract
Loading... -
+
P1.01-124 - Health-Related Quality of Life (HRQoL) Data in a Phase 3 Study of First-Line Brigatinib vs Crizotinib in NSCLC (ALTA-1L)
09:45 - 09:45 | Presenter: Rosario Garcia Campelo
- Abstract
Loading... -
+
P1.01-125 - Uniportal Versus Multiportal Thoracoscopic Lobectomy with Systematic Mediastinal Lymphadenectomy for N2(+) Stage III NSCLC (Now Available)
09:45 - 09:45 | Presenter: Youjun Deng
- Abstract
Loading... -
+
P1.01-126 - The Co-Occurring Genomic Landscape of ERBB2 Exon 20 Insertion in Non-Small Cell Lung Cancer (NSCLC) and the Potential Indicator of Response to Afatinib (Now Available)
09:45 - 09:45 | Presenter: Bo Yuan
- Abstract
Loading... -
+
P1.01-127 - Antitumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 in NSCLC with EGFR Exon 20 Insertions
09:45 - 09:45 | Presenter: Gregory J Riely
- Abstract
Loading... -
+
P1.01-128 - Choice of Postoperative Radiotherapy for Resected IIIA-N2 Non-Small Cell Lung Cancer: Impact of Log Odds of Positive Lymph Nodes (Now Available)
09:45 - 09:45 | Presenter: Yang Wo
- Abstract
Loading... -
+
P1.01-129 - Preclinical Genetic Evaluation of Alternating ALK TKI Therapy Versus Continuous Dosing in ALK NSCLC to Inform the ALKternate Clinical Trial
09:45 - 09:45 | Presenter: Malinda Itchins
- Abstract
Loading... -
+
P1.01-130 - Clinical Experience with Nintedanib in Previously Treated Non-Small Cell Lung Cancer in Spain: A Retrospective Multicenter Study (Now Available)
09:45 - 09:45 | Author(s): Patricia Cruz
- Abstract
Loading... -
+
P1.01-131 - The Comparison Between Non-Intubated and Intubated Anesthesia Video-Assisted Thoracoscopic Surgery: A Meta-Analysis
09:45 - 09:45 | Presenter: Guanping Qiu
- Abstract
Loading... -
+
P1.01-132 - Clinicopathological and Genomic Comparisons Between Different Histologic Components in Combined Small Cell and Non-Small Cell Lung Cancer
09:45 - 09:45 | Presenter: Mong-Wei Lin
- Abstract
Loading... -
+
P1.01-133 - Randomized Open-Label Study of Bintrafusp Alfa (M7824) vs Pembrolizumab in Patients with PD-L1 Expressing Advanced 1L NSCLC (Now Available)
09:45 - 09:45 | Presenter: Myung-Ju Ahn
- Abstract
Loading... -
+
P1.01-134 - SAVANNAH: Phase II Trial of Osimertinib + Savolitinib in EGFR-Mutant, MET-Driven Advanced NSCLC, Following Prior Osimertinib
09:45 - 09:45 | Presenter: Myung-Ju Ahn
- Abstract
Loading... -
+
P1.01-135 - Salvage Chemotherapy After Immunotherapy Failure in Non-Small-Cell Lung Cancer Patients (Now Available)
09:45 - 09:45 | Author(s): Giovanni Randon
- Abstract
Loading... -
+
P1.01-136 - Uncommon EGFR Mutations in Non-Small Cell Lung Cancer: A Systematic Literature Review of Prevalence and Clinical Outcomes
09:45 - 09:45 | Presenter: Tom John
- Abstract
Loading... -
+
P1.01-137 - KNSTRN Promotes Non-Small Cell Lung Cancer Progress and Attenuates Radiosensitivity via Activating EGFR-ERK1/2-E2F1 Pathway
09:45 - 09:45 | Author(s): Shijing Ma
- Abstract
Loading...
-
+
P1.03 - Biology
- Type: Poster Viewing in the Exhibit Hall
- Track: Biology
- Presentations: 11
- Now Available
- Coordinates: 9/08/2019, 09:45 - 18:00, Exhibit Hall
-
+
P1.03-01 - Polymorphisms in Glycolysis-Related Genes Are Associated with Clinical Outcomes of Paclitaxel-Cisplatin Chemotherapy in NSCLC
09:45 - 09:45 | Presenter: Sun Ha Choi
- Abstract
Loading... -
+
P1.03-02 - Nintedanib Selectively Inhibits Angiogenesis Induced by the Conditioned Medium of Lung Adenocarcinoma TAFs in Vitro
09:45 - 09:45 | Presenter: Natalia Isabel Díaz-Valdivia
- Abstract
Loading... -
+
P1.03-03 - Inhibition of H1299 Lung Cancer Cell Proliferation and Survival by Rosemary Extract Is Associated with AMPK Activation
09:45 - 09:45 | Presenter: Evangelia Litsa Tsiani
- Abstract
Loading... -
+
P1.03-04 - Use Supernatant of Malignant Pleural Effusion to Identify Driver Mutants and Monitor Response to Targeted Therapy
09:45 - 09:45 | Author(s): Yuehong Wang
- Abstract
Loading... -
+
P1.03-05 - COMMD4 in Lung Cancer: Towards a New Therapeutic Target and Diagnostic Biomarker
09:45 - 09:45 | Author(s): Amila Suraweera
- Abstract
Loading... -
+
P1.03-06 - Integrative Omics Analysis Reveals Important Roles of Adenosine Diphosphate in Haemostasis and Platelet Activation in NSCLC
09:45 - 09:45 | Presenter: Long Hoang
- Abstract
Loading... -
+
P1.03-07 - Advantages and Setbacks of EGFR Mutation Testing from Liquid Biopsy of Advanced Lung Adenocarcinoma Patients in Serbia
09:45 - 09:45 | Presenter: Jelena Spasic
- Abstract
Loading... -
+
P1.03-08 - RNF43 Ubiquitinates and Degrades Phosphorylated E-Cadherin by c-Src to Facilitate Epithelial-Mesenchymal Transition in Lung Adenocarcinoma
09:45 - 09:45 | Presenter: Yang Zhao
- Abstract
Loading... -
+
P1.03-09 - Atypical Ubiquitin as a Molecular Target in Lung Cancer
09:45 - 09:45 | Presenter: Seshiru Nakazawa
- Abstract
Loading... -
+
P1.03-10 - High-Risk Growth Patterns of Lung Adenocarcinoma Show Distinct Modes of Metastasis and Recurrence
09:45 - 09:45 | Presenter: Marco Sereno
- Abstract
Loading... -
+
P1.03-11 - Molecular Testing of Small Bronchoscopy Specimens Using NanoString Technology
09:45 - 09:45 | Presenter: Brielle Anne Parris
- Abstract
Loading... -
+
P1.03-12 - Preclinical Validation of an Epigenetic Panel of Seven miRNAs at Early Stages NSCLC Patients and Its Prognostic Implications (Now Available)
09:45 - 09:45 | Presenter: Dario Sanchez Cabrero
- Abstract
Loading... -
+
P1.03-13 - Genomic Landscape of Brazilian Non-Small Cell Lung Cancer
09:45 - 09:45 | Presenter: Letícia Ferro Leal
- Abstract
Loading... -
+
P1.03-14 - HLA-E and FAT1 in Head and Neck and Lung Cancer. The Effect of Osimertinib or Olmutinib with Artesunate (Dihydroartemisinin)
09:45 - 09:45 | Presenter: Imane Chaib
- Abstract
Loading... -
+
P1.03-15 - Non-Invasive Detection of Secondary Resistance Mutations in ALK-Positive NSCLC Patients by Next-Generation Sequencing
09:45 - 09:45 | Author(s): Estela Sánchez Herrero
- Abstract
Loading... -
+
P1.03-16 - Anti-Tumor Effect of Pan-RAF Inhibitor in NSCLC Cells Harboring BRAF Mutation (Now Available)
09:45 - 09:45 | Presenter: Shunsaku Miyauchi
- Abstract
Loading... -
+
P1.03-17 - Function of Antisense LncRNA RP11-539E17.5 and FAM83A-AS1 Up-Regulating FAM83A in Lung Adenocarcinoma Tumorigenesis and Development (Now Available)
09:45 - 09:45 | Presenter: Xuequan Wang
- Abstract
Loading... -
+
P1.03-18 - OCIAD2 Impairs Mitochondria-Mediated Apoptosis Through Substantial Alteration of Crista Structure in Lung Adenocarcinoma
09:45 - 09:45 | Presenter: Jeongmin Hong
- Abstract
Loading... -
+
P1.03-19 - Circulating Tumour Cells in Non-Small Cell Lung Cancer
09:45 - 09:45 | Presenter: Kenneth John O’Byrne
- Abstract
Loading... -
+
P1.03-20 - Exploring Driver Mutations in Non-Coding RNAs in Lung Adenocarcinoma
09:45 - 09:45 | Presenter: Alvaro Andrades
- Abstract
Loading... -
+
P1.03-21 - Epigenome-Wide Association Study of Cancer Associated Fibroblasts-Induced Oncogenic Transformation of Lung Epithelial Cells
09:45 - 09:45 | Presenter: Sheng-Fang Su
- Abstract
Loading... -
+
P1.03-22 - A Novel Method for Detecting Low Abundant Mutants in Three Types of Liquid Biopsies by Capturing Mutant-Alleles
09:45 - 09:45 | Presenter: Rui Lin
- Abstract
Loading... -
+
P1.03-23 - Delta-Like 1 Homolog (DLK1) Expression in Non-Small-Cell Lung Cancer and the Development of Radioimmunotherapy Targeting DLK1
09:45 - 09:45 | Presenter: Hironori Takagi
- Abstract
Loading... -
+
P1.03-24 - Thoracic Injection of PD-1 Blocking Antibody Improves the Murine Model of Malignant Pleural Effusion
09:45 - 09:45 | Author(s): Xin-ying Li
- Abstract
Loading... -
+
P1.03-25 - Synergistic Lethality of Ferroptosis Inducer-Disulfiram/Copper Complex and WEE1 Kinase Inhibitor for RAS/TP53 Mutant NSCLC
09:45 - 09:45 | Presenter: Bo Su
- Abstract
Loading... -
+
P1.03-26 - Genetic and Molecular Profiling of Non-Smoking Related Lung Adenocarcinomas
09:45 - 09:45 | Presenter: Eva Pros
- Abstract
Loading... -
+
P1.03-27 - Aspirin Overcomes Acquired Resistance to Osimertinib in Human Lung Cancer Cells via Bim-Dependent Apoptosis Induction
09:45 - 09:45 | Presenter: He Yong
- Abstract
Loading... -
+
P1.03-28 - Prognostic Value of Estrogen Receptor Beta Tumor Expression in Non-Small Cell Lung Cancer Patients After Radical Surgery
09:45 - 09:45 | Presenter: Anna Basharina
- Abstract
Loading... -
+
P1.03-29 - Cellular Biology Determines Ability of XIST to Act as a miRNA Sponge in Non-Small Cell Lung Cancer
09:45 - 09:45 | Presenter: Greg L Stewart
- Abstract
Loading... -
+
P1.03-30 - Transcriptome Signatures of Tobacco Carcinogens on Lung Adenocarcinoma Cell Lines
09:45 - 09:45 | Presenter: Mario Pepe
- Abstract
Loading... -
+
P1.03-31 - BRAF Mutations: Classes I, II and III in NSCLC Patients Included in the SLLIP Trial, Targeted Treatment According to Class (Now Available)
09:45 - 09:45 | Presenter: Jillian Wilhelmina Paulina Bracht
- Abstract
Loading... -
+
P1.03-32 - Knockdown of CENPF Gene Inhibits the Progression of Lung Adenocarcinoma Mediated by ERβ2/5 Pathway (Now Available)
09:45 - 09:45 | Presenter: Hexiao Tang
- Abstract
Loading... -
+
P1.03-33 - Analysis of Lipid Metabolism Genes in Advanced Small Cell Lung Cancer
09:45 - 09:45 | Author(s): María Merino
- Abstract
Loading... -
+
P1.03-34 - The lncRNA NEAT1 Promotes Radioresistance via the MiR-491-5p/CAPG Axis in NSCLC (Now Available)
09:45 - 09:45 | Presenter: Suna Zhou
- Abstract
Loading... -
+
P1.03-35 - Analysis of TET2 Gene Aberrations in East Asian Non-Small-Cell Lung Cancer Patients and Evaluation of Their Prognosis
09:45 - 09:45 | Author(s): Yinbin Zhang
- Abstract
Loading... -
+
P1.03-36 - Cell-Free DNA Levels in Liquid Biopsy from Patients with Non-Small Cell Lung Cancer and Association with Clinical Parameters and Disease Outcome
09:45 - 09:45 | Author(s): Natalia Zampieri Pontes
- Abstract
Loading... -
+
P1.03-37 - Impacts of DSB Repair Protein, NBS1, on Lung Cancer (Now Available)
09:45 - 09:45 | Presenter: Yu-Feng Wei
- Abstract
Loading... -
+
P1.03-38 - EGFR Mutation Status as a Prognostic Marker in Stage 1 Lung Adenocarcinoma After Definitive Surgical Resection (Now Available)
09:45 - 09:45 | Presenter: Carlos Galvez
- Abstract
Loading... -
+
P1.03-39 - Intra-Tumoral CD61+ Megakaryocytes Predicts Poor Prognosis in Non-Small Cell Lung Cancer
09:45 - 09:45 | Presenter: Wenhua Liang
- Abstract
Loading... -
+
P1.03-40 - Using Model Systems to Improve Outcomes for Early Stage NSCLC
09:45 - 09:45 | Presenter: Matthew Allen Steliga
- Abstract
Loading... -
+
P1.03-41 - Chronic Nicotine Exposure Affects PD-L1 Expression and Sensitivity to EGFR-TKI in Lung Cancer
09:45 - 09:45 | Presenter: Changdong Yeo
- Abstract
Loading... -
+
P1.03-42 - Angiotensin System Inhibitors Improve Survival in Stage IIIA NSCLC and Show Anti-Tumor Effect in Combination with Chemotherapy in a Model of NSCLC (Now Available)
09:45 - 09:45 | Presenter: Hexiao Tang
- Abstract
Loading... -
+
P1.03-43 - Preoperative Prognostic Value of Immune-Inflammation Index in Patients with Operable Non-Small Cell Lung Cancer (Now Available)
09:45 - 09:45 | Presenter: Carlos Alfredo Fraile Olivero
- Abstract
Loading... -
+
P1.03-44 - Role of Serum Procalcitonin as Diagnostic Biomarker of Pneumonia in Lung Cancer Patient
09:45 - 09:45 | Presenter: Atit Puspitasari Dewi
- Abstract
Loading... -
+
P1.03-45 - Circulating Tumor Cells' Clearance in Blood Samples After Chemotherapy: A Good Prognostic Factor for OS in Advanced NSCLC
09:45 - 09:45 | Presenter: Lucia Milla Collado
- Abstract
Loading... -
+
P1.03-47 - KEAP1 Mutations in East Asian Patients with NSCLC: An Investigation of Prevalence, Clinicopathologic Characteristics and Prognosis
09:45 - 09:45 | Author(s): Zongyang Yu
- Abstract
Loading... -
+
P1.03-48 - Vasohibin 2 Promotes Angiogenesis and Lymphangiogenesis of Lung Squamous Cell Carcinoma Through Snail-Dependent VEGF-D Signaling Pathway
09:45 - 09:45 | Presenter: Pengpeng Liu
- Abstract
Loading... -
+
P1.03-49 - Systematic Dysregulation of Cell Cycle by lncRNAs in Lung Adenocarcinoma (Now Available)
09:45 - 09:45 | Presenter: Xiaoshun Shi
- Abstract
Loading... -
+
P1.03-50 - Type- and Stage-Specific Genomic Profiles in East Asian Lung Cancer Patients with No TKI-Related Driver Gene Mutations
09:45 - 09:45 | Presenter: Yayi He
- Abstract
Loading... -
+
P1.03-51 - MUC3A Induces PD-L1 and Reduces Tyrosine Kinase Inhibitor Effects in EGFR-Mutant Non-Small Cell Lung Cancer
09:45 - 09:45 | Author(s): Yuan Luo
- Abstract
Loading...
-
+
P1.04 - Immuno-oncology
- Type: Poster Viewing in the Exhibit Hall
- Track: Immuno-oncology
- Presentations: 27
- Now Available
- Coordinates: 9/08/2019, 09:45 - 18:00, Exhibit Hall
-
+
P1.04-01 - Body Mass Index and Age Do Not Influence Survival in Patients with Lung Cancers Treated with PD1/PDL1 Immune Checkpoint Inhibitors
09:45 - 09:45 | Presenter: Corentin Richard
- Abstract
Loading... -
+
P1.04-02 - Efficacy and Safety of Sintilimab with Anlotinib as First-Line Therapy for Advanced Non-Small Cell Lung Cancer (NSCLC)
09:45 - 09:45 | Presenter: Baohui Han
- Abstract
Loading... -
+
P1.04-03 - HLA Affinity for Mutant EGFR Derived Peptides Identifies a Group of Patients with EGFR Driven NSCLC and Favorable Prognosis
09:45 - 09:45 | Presenter: Anastasios Dimou
- Abstract
Loading... -
+
P1.04-04 - DNA Damage Response Gene Alterations Are Associated with High Tumor Mutational Burden and Clinical Benefit from PD-1 Axis Inhibition in NSCLC (Now Available)
09:45 - 09:45 | Presenter: Biagio Ricciuti
- Abstract
Loading... -
+
P1.04-05 - PD-L1 Expression (SP263) in Lung Cancer and Paired Brain Metastases – A Single Center Study in 211 Patients
09:45 - 09:45 | Author(s): Alexandra Kündig
- Abstract
Loading... -
+
P1.04-06 - Tumor Microenvironment Landscape in Lung Adenocarcinoma by Single-Cell Sequencing
09:45 - 09:45 | Presenter: Bo Mi Ku
- Abstract
Loading... -
+
P1.04-07 - Immune Suppressive Microenvironment and Highly Clonal Concordance of TCR Repertoire in Brain Metastases from Non-Small Cell Lung Cancer
09:45 - 09:45 | Presenter: Yujin Kudo
- Abstract
Loading... -
+
P1.04-08 - Randomized Controlled Phase III Trial of Adjuvant Chemoimmunotherapy to Lung Cancer Patients: Results of Malignant Effusions
09:45 - 09:45 | Presenter: Hideki Kimura
- Abstract
Loading... -
+
P1.04-09 - Predictive Clinical and Molecular Features of Long-Term Survivors Receiving Immune Checkpoint Inhibitors for Stage 4 Non-Small Cell Lung Cancer (Now Available)
09:45 - 09:45 | Presenter: Aaron John Franke
- Abstract
Loading... -
+
P1.04-10 - Identification of Immunotherapy Targets in STK11 Mutant Non-Squamous Non-Small Cell Lung Cancer
09:45 - 09:45 | Presenter: Edwin Yau
- Abstract
Loading... -
+
P1.04-11 - Depicting the Intra-Tumoral Viral and Microbial Landscape of Localized NSCLC Using Standard Next Generation Sequencing Data
09:45 - 09:45 | Presenter: Pierre-Olivier Gaudreau
- Abstract
Loading... -
+
P1.04-12 - Tumor Uptake and Biodistribution of 89Zr-Labeled Pembrolizumab in Patients with Metastatic Non-Small-Cell Lung Cancer (Now Available)
09:45 - 09:45 | Presenter: Anna-Larissa Nadia Niemeijer
- Abstract
Loading... -
+
P1.04-13 - Delineating Spatial Heterogeneity of Tumor Mutational Burden (TMB) Counts in Pulmonary Adenocarcinoma
09:45 - 09:45 | Presenter: Daniel Kazdal
- Abstract
Loading... -
+
P1.04-14 - Early Changes in Plasma CXCL2 and MMP2 Levels Predicts the Response to Anti-PD-1 Therapy in Non-Small-Cell Lung Cancer
09:45 - 09:45 | Presenter: Norikazu Matsuo
- Abstract
Loading... -
+
P1.04-15 - Smoking Status Is Not a Replacement Biomarker for Tumor Mutation Burden in Non-Small Lung Cancer
09:45 - 09:45 | Author(s): Michael Sharpnack
- Abstract
Loading... -
+
P1.04-16 - Early Antibiotic Use Affects the Efficacy of First Line Immunotherapy in Lung Cancer Patients but Route of Administration Seems to be Decisive
09:45 - 09:45 | Presenter: Xabier Mielgo Rubio
- Abstract
Loading... -
+
P1.04-17 - Phase I/II Study of Nivolumab and Vorolanib in Patients with Refractory Thoracic Tumors
09:45 - 09:45 | Author(s): Jennifer G. Whisenant
- Abstract
Loading... -
+
P1.04-18 - Interleukin-5 Drives the Expansion of Pulmonary B-1 B Cells and Restricts Lung Tumor Growth (Now Available)
09:45 - 09:45 | Presenter: Rachel A Cederberg
- Abstract
Loading... -
+
P1.04-19 - Association Between Efficacy and irAEs in Patients with Advanced Non-Small Cell Lung Cancer Receiving Immune-Checkpoint Inhibitors
09:45 - 09:45 | Presenter: Mariona Riudavets
- Abstract
Loading... -
+
P1.04-20 - PD-L1 mRNA Derived from Tumor-Educated Platelets Predicts the Clinical Outcome of Immunotherapy in Non-Small Cell Lung Cancer
09:45 - 09:45 | Presenter: Jianhua Chang
- Abstract
Loading... -
+
P1.04-21 - Cellular Landscape of Normal Adjacent to Tumor Microenvironment in Non-Small Cell Lung Cancer
09:45 - 09:45 | Presenter: Yuan Li
- Abstract
Loading... -
+
P1.04-22 - Potential DNA Repair Biomarker for Response to Immunotherapy of Lung Cancer Patients
09:45 - 09:45 | Presenter: Zvi Livneh
- Abstract
Loading... -
+
P1.04-23 - Characterizing the Tumor Immune Microenvironment of Non-Small Cell Lung Carcinoma in People Living with HIV Using Imaging Mass Cytometry
09:45 - 09:45 | Presenter: Ramsey Yusuf
- Abstract
Loading... -
+
P1.04-24 - Circulating Suppressive Immune Cells Predict the Efficacy of Anti PD-1 Immunotherapy in Patients with Advanced Non-Small Cell Lung Cancer
09:45 - 09:45 | Presenter: Jiae Koh
- Abstract
Loading... -
+
P1.04-25 - CT Based Vessel Tortuosity Features Are Prognostic of Overall Survival and Predictive of Immunotherapy Response in NSCLC Patients
09:45 - 09:45 | Author(s): Mehdi Alilou
- Abstract
Loading... -
+
P1.04-26 - EMT-Associated Response and Resistance to MEK Inhibitor and Immune Checkpoint Blockade Combinations in KRAS-Mutant NSCLC
09:45 - 09:45 | Presenter: Pierre-Olivier Gaudreau
- Abstract
Loading... -
+
P1.04-27 - Processing Escapes: Novel Resistance Mechanisms Under Immune Checkpoint Inhibition in NSCLC (Now Available)
09:45 - 09:45 | Presenter: Michael Wessolly
- Abstract
Loading... -
+
P1.04-28 - COAST: Durvalumab Alone or with Novel Agents for Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer
09:45 - 09:45 | Presenter: Roy S. Herbst
- Abstract
Loading... -
+
P1.04-29 - Dynamic Changes of Plasma PD-L1 mRNA Expression Predict Response to Anti-PD-1/Anti-PD-L1 Treatment in Malignancies (Now Available)
09:45 - 09:45 | Presenter: Jianguo Sun
- Abstract
Loading... -
+
P1.04-30 - Pioneer Study: Precision Immuno-Oncology for Advanced Non-Small Cell Lung Cancer Patients with PD1/L1 ICI Resistance
09:45 - 09:45 | Presenter: Fabrice Barlesi
- Abstract
Loading... -
+
P1.04-31 - Immunosenescence Correlates with Poor Outcome from PD-(L)1 Blockade but Not Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) (Now Available)
09:45 - 09:45 | Presenter: Roberto Ferrara
- Abstract
Loading... -
+
P1.04-32 - Ki67+ PD-1+ Central Memory CD8 T-Cell Frequencies Predict Response Upon Nivolumab+Ipilimumab in Malignant Pleural Mesothelioma
09:45 - 09:45 | Presenter: Joanne Marijke Mankor
- Abstract
Loading... -
+
P1.04-33 - Deep Phenotyping of Immune Populations Reveals Baseline Predictors of Pembrolizumab Efficacy in NSCLC on KEYNOTE-001 (Now Available)
09:45 - 09:45 | Presenter: Philippe Rochigneux
- Abstract
Loading... -
+
P1.04-34 - Efficacy and Safety of First-Line Pembrolizumab Monotherapy in Elderly Patients (Aged ≥ 75 years) with Non-Small Cell Lung Cancer
09:45 - 09:45 | Presenter: Tomohide Sugiyama
- Abstract
Loading... -
+
P1.04-35 - Identification and Characterization of a Unique KLRG1-Expressing Subset of CD4+FOXP3+ Tregs in Non-Small Cell Lung Cancer (Now Available)
09:45 - 09:45 | Presenter: Dennis Adeegbe
- Abstract
Loading... -
+
P1.04-36 - An in Vivo Inflammatory Loop Potentiates KRAS Blockade
09:45 - 09:45 | Presenter: Kristina Anna Maria Arendt
- Abstract
Loading... -
+
P1.04-37 - Dioscin Elicits Anti-Tumor Immunity by Inhibiting Macrophages M2 Polarization via JNK and STAT3 Pathways in Lung Cancer
09:45 - 09:45 | Presenter: Yinan Yao
- Abstract
Loading... -
+
P1.04-38 - Efficacy and Safety of Immunotherapy in Elderly Patients with Non-Small Cell Lung Cancer (Now Available)
09:45 - 09:45 | Author(s): Giulia Galli
- Abstract
Loading... -
+
P1.04-39 - Molecular Characteristics, Immunophenotype, and Immune Checkpoint Inhibitor Response in BRAF Non-V600 Mutant Lung Cancers
09:45 - 09:45 | Presenter: Michael Offin
- Abstract
Loading... -
+
P1.04-40 - Serum Perforin Levels During the First Cycle of Anti-PD-1 Antibody Therapies in Non-Small Cell Lung Cancer
09:45 - 09:45 | Presenter: Takayo Ota
- Abstract
Loading... -
+
P1.04-41 - Immunotherapy Concomitant to Radiotherapy: A Multicentric Retrospective Study on 179 Patients with Advanced Non-Small Cell Lung Cancer (Now Available)
09:45 - 09:45 | Presenter: Alessio Bruni
- Abstract
Loading... -
+
P1.04-42 - Tumor Microenvironment Is Associated with Efficacy of PD-1/PD-L1 Inhibitors in Patients with Primary Pulmonary Lymphoepithelioma-Like Cancer (Now Available)
09:45 - 09:45 | Author(s): Kai Yin
- Abstract
Loading... -
+
P1.04-43 - PD-RAD: A Translational Study Investigating PD-L1 Expression After Radiotherapy for Non-Small Cell Lung Cancer - Trial in Progress
09:45 - 09:45 | Presenter: Tiana Kordbacheh
- Abstract
Loading... -
+
P1.04-44 - Radiomics for Predicting Response to First-Line Anti-PD1 Therapy in Advanced NSCLC (Now Available)
09:45 - 09:45 | Presenter: Christoph Jakob Ackermann
- Abstract
Loading... -
+
P1.04-45 - Immune-Oncology Gene Expression Profiles Allow Lung Cancer Patients’ Stratification and Identification of Responders to Immunotherapy
09:45 - 09:45 | Presenter: Fabrizio Tabbò
- Abstract
Loading... -
+
P1.04-46 - PD-1 Inhibitor Plus Chemotherapy as 2nd/Subsequent Line Setting Demonstrate Superior Efficacy Over PD-1 Inhibitor Alone in Pts of Advanced NSCLC
09:45 - 09:45 | Presenter: Shengxiang Ren
- Abstract
Loading... -
+
P1.04-47 - Tumor Mutation Burden Through Hybrid Capture – Circulating Tumor DNA May Predict Response to Immunotherapy in NSCLC
09:45 - 09:45 | Presenter: Roxana Denisa Grinberg
- Abstract
Loading... -
+
P1.04-48 - Prediction of Tumor Doubling Time of Lung Adenocarcinoma Using Radiomics Margin Characteristics (Now Available)
09:45 - 09:45 | Presenter: Hyun Jung Yoon
- Abstract
Loading... -
+
P1.04-49 - Quantitative Computed Tomography (CT) Based Texture Analysis (QTA) Might Identify Responders to Immunotherapy in Non-Small Cell Lung Cancer
09:45 - 09:45 | Presenter: Zsolt Megyesfalvi
- Abstract
Loading... -
+
P1.04-50 - Real World Efficacy of Pembrolizumab of as a 1st Line Treatment in Metastatic Non-Small Cell Lung Cancer with PD-L1 High Expression (Now Available)
09:45 - 09:45 | Presenter: Kazuo Kasahara
- Abstract
Loading... -
+
P1.04-51 - Treatment with Immune Checkpoint Inhibitors for Advanced NSCLC in Elderly and Frail Patients. A Real-Life Experience (Now Available)
09:45 - 09:45 | Presenter: Karen Fuglsang Junker
- Abstract
Loading... -
+
P1.04-52 - The Role of Blood Biomarkers in Radiation Therapy for Thoracic Malignancies
09:45 - 09:45 | Presenter: Eleni Gkika
- Abstract
Loading... -
+
P1.04-53 - A High PD-L1 Expression in Non-Small Cell Lung Cancer Correlates with Expression of SPOP and CD8 Tumor-Infiltrating Lymphocytes (Now Available)
09:45 - 09:45 | Presenter: Masaaki Inoue
- Abstract
Loading... -
+
P1.04-54 - Inter-Tumor Heterogeneity of PD-L1 Expressions in Non-Small Cell Lung Cancer
09:45 - 09:45 | Presenter: Yuichi Saito
- Abstract
Loading... -
+
P1.04-55 - Comparison of PD-L1 Expression Status Between Pure-Solid Versus Part-Solid Tumors in Lung Adenocarcinomas
09:45 - 09:45 | Presenter: Kenichi Suda
- Abstract
Loading... -
+
P1.04-56 - Landscape of Tumor Mutational Burden in Indian NSCLC Patients
09:45 - 09:45 | Presenter: Prashant Mehta
- Abstract
Loading... -
+
P1.04-57 - Metronomic Dosing of Chemotherapy Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Non-Small Cell Lung Cancer (Now Available)
09:45 - 09:45 | Presenter: Yijun Jia
- Abstract
Loading... -
+
P1.04-58 - Uncovering the Tumor Microenvironment of KRAS-Driven Lung Adenocarcinoma: The Link Between Th17 Signaling and B Cell
09:45 - 09:45 | Author(s): Simona De Summa
- Abstract
Loading... -
+
P1.04-59 - Modified Glasgow Prognostic Score Predict Survival Among Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors (Now Available)
09:45 - 09:45 | Presenter: Cláudia Freitas
- Abstract
Loading... -
+
P1.04-60 - Impact of Metastatic Location on Survival in Stage-IV Non-Small Cell Lung Cancer (NSCLC) Treated with Immunotherapy
09:45 - 09:45 | Author(s): abdul rafeh Naqash
- Abstract
Loading... -
+
P1.04-61 - Neutrophil-Lymphocyte Ratio: A Predictive Biomarker of Immunotherapy in Lung Cancer? (Now Available)
09:45 - 09:45 | Author(s): Maria Aurora Mendes
- Abstract
Loading... -
+
P1.04-62 - Nomogram Based on Multivariable Regression Model Estimates the Overall Survival of Nivolumab for Previously Treated Advanced NSCLC
09:45 - 09:45 | Presenter: Motohiro Tamiya
- Abstract
Loading... -
+
P1.04-63 - Correlation of Mutations in TP53, CDKN2A and PIK3CA with VISTA Expression in Pleomorphic Lung Carcinoma
09:45 - 09:45 | Presenter: Adam Januszewski
- Abstract
Loading... -
+
P1.04-64 - The Opposite Role of PD-L1 Expression in EGFR Mutant Lung Cancer Treated with PD-1 Inhibitor Before and After EGFR TKI: Pilot Study
09:45 - 09:45 | Presenter: Hyung Soon Park
- Abstract
Loading... -
+
P1.04-65 - Microenvironment-Derived ADAM28 Impacts the Onset of Lung Cancer (Now Available)
09:45 - 09:45 | Presenter: Céline Hubeau
- Abstract
Loading... -
+
P1.04-66 - The Percentage of PD-L1 Besides 50% Positivity Predicts Objective Response to Pembrolizumab in Non-Small Cell Lung Cancer
09:45 - 09:45 | Presenter: Anello Marcello Poma
- Abstract
Loading... -
+
P1.04-67 - First-Line Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer (NSCLC) – A Network Meta-Analysis by PD-L1
09:45 - 09:45 | Author(s): Pui San Tan
- Abstract
Loading... -
+
P1.04-68 - Liver Metastases Predicts Poorer Prognosis in Advanced NSCLC Patients Who Receiving Nivolumab Monotherapy
09:45 - 09:45 | Presenter: Guowei Zhang
- Abstract
Loading... -
+
P1.04-69 - Modelling the Immunosuppressive Difference of SBRT and CRT by Simulating the Dose to Circulating Lymphocytes in Non-Small Cell Lung Cancer (Now Available)
09:45 - 09:45 | Author(s): Yichao Shen
- Abstract
Loading... -
+
P1.04-70 - Application of Tumor Kinetics for Evaluation of Hyperprogression in Immune Checkpoint Inhibitor Treatment for Non-Small Cell Lung Cancer (Now Available)
09:45 - 09:45 | Presenter: Cheol-Kyu Park
- Abstract
Loading... -
+
P1.04-71 - Tumor Burden Is Not Associated with Efficacy of Immune Checkpoint Inhibitors in Advanced Lung Cancer
09:45 - 09:45 | Presenter: David E. Gerber
- Abstract
Loading... -
+
P1.04-72 - Tumor Mutational Burden as a Potential Predictive Biomarker of Response to PD-1/PD-L1 Blockade in Non-Small Cell Lung Cancer
09:45 - 09:45 | Presenter: Hyojin Kim
- Abstract
Loading... -
+
P1.04-73 - Small Cell Transformation of Non-Small Cell Lung Cancer (NSCLC) on Immune Checkpoint Inhibitors: Case Report and Literature Review
09:45 - 09:45 | Presenter: Kartik Sehgal
- Abstract
Loading... -
+
P1.04-74 - Characteristics of T Cell Receptor Repertoire of Lung Cancer Patients (Now Available)
09:45 - 09:45 | Presenter: Naixin Liang
- Abstract
Loading... -
+
P1.04-75 - Immune-Related Adverse Events and the Neutrophil to Lymphocyte Ratio as Predictors of Clinical Response to Immunotherapy (Now Available)
09:45 - 09:45 | Author(s): Hermán Wesley Powery
- Abstract
Loading... -
+
P1.04-76 - Predictive Factors of Early Therapeutic Failure to Immunotherapy in Patients with Metastatic NSCLC
09:45 - 09:45 | Presenter: Victor Aurelio Ramos Sousa
- Abstract
Loading... -
+
P1.04-77 - Efficacy of Anti-PD-1/L1 Therapy for Advanced Non-Small Cell Lung Cancer with Preexisting Autoimmune Markers
09:45 - 09:45 | Presenter: Takako Inoue
- Abstract
Loading... -
+
P1.04-78 - Efficacy of Checkpoint Inhibitors in Combination with Chemotherapy for First-Line Treatment of Advanced Non-Squamous NSCLC (Now Available)
09:45 - 09:45 | Presenter: Kyaw Zin Thein
- Abstract
Loading... -
+
P1.04-79 - CD73 Expression in Lung Adenocarcinomas and Immunological and Molecular Associations
09:45 - 09:45 | Author(s): Pedro Rocha
- Abstract
Loading... -
+
P1.04-80 - Immunotherapy-Related Thrombosis: Considerations and Associated Factors in Non-Small Cell Lung Cancer (NSCLC) Patients
09:45 - 09:45 | Author(s): Andrés Felipe Cardona
- Abstract
Loading... -
+
P1.04-81 - Characterization of Hispanic Patients Who Experienced Hyperprogression During Treatment for Advanced NSCLC with Immunotherapy
09:45 - 09:45 | Presenter: Oscar Gerardo Arrieta
- Abstract
Loading... -
+
P1.04-82 - Toxicity as a Clinical Marker for Efficacy of Immunotherapy in NSCLC: A Multicentric Experience from Argentina (Now Available)
09:45 - 09:45 | Presenter: Maria Florencia Rizzi
- Abstract
Loading... -
+
P1.04-83 - Combining Immune Gene Polymorphism and Immune Profile Predicts Brain Metastases and Death in a Brazilian Cohort of Non-Small Cell Lung Carcinoma
09:45 - 09:45 | Author(s): Juliana Machado-Rugolo
- Abstract
Loading... -
+
P1.04-84 - MiR-195 Restrains Lung Adenocarcinoma via Regulating CD4+ T Cell Activation Through CCDC88C/Wnt Signaling Pathway
09:45 - 09:45 | Author(s): Cheng Yuan
- Abstract
Loading...
-
+
P1.06 - Mesothelioma
- Type: Poster Viewing in the Exhibit Hall
- Track: Mesothelioma
- Presentations: 7
- Now Available
- Coordinates: 9/08/2019, 09:45 - 18:00, Exhibit Hall
-
+
P1.06-01 - Combining Immunoprofile, Immunogenic Collagen and Mismatch Repair Proteins Predicts Risk of Death and Target Therapy in Malignant Mesothelioma (Now Available)
09:45 - 09:45 | Presenter: Juliana Machado-Rugolo
- Abstract
Loading... -
+
P1.06-02 - National Trends in Outcomes in Patients with Malignant Pleural Mesothelioma
09:45 - 09:45 | Presenter: Kaushal Parikh
- Abstract
Loading... -
+
P1.06-03 - Selective Depletion of Foxp3+ Regulatory T Cells After Local Radiotherapy Induces Abscopal Effects in Murine Malignant Mesothelioma
09:45 - 09:45 | Presenter: Mikihiro Kohno
- Abstract
Loading... -
+
P1.06-04 - Deep Learning-Based Segmentation of Mesothelioma on CT Scans: Application to Patient Scans Exhibiting Pleural Effusion (Now Available)
09:45 - 09:45 | Author(s): Eyjolfur Gudmundsson
- Abstract
Loading... -
+
P1.06-05 - Clinical Features and Outcomes of Recurrence After Pleurectomy/Decortication for Malignant Pleural Mesothelioma
09:45 - 09:45 | Presenter: Akifumi Nakamura
- Abstract
Loading... -
+
P1.06-06 - EORTC 1205: Randomized Study of Pleurectomy/Decortication (P/D) Preceded or Followed by Chemotherapy in Malignant Pleural Mesothelioma
09:45 - 09:45 | Presenter: Jan P Van Meerbeeck
- Abstract
Loading... -
+
P1.06-07 - Targeting Photo-Therapy for Malignant Pleural Mesothelioma; Near Infrared Photoimmunotherapy Targeting Podoplanin
09:45 - 09:45 | Presenter: Yuko Nishinaga
- Abstract
Loading... -
+
P1.06-08 - WDPM-Like but Not Cribriform as Secondary Growth Patterns Modify Survival in Epithelioid Malignant Pleural Mesothelioma
09:45 - 09:45 | Presenter: Yu Zhi Zhang
- Abstract
Loading... -
+
P1.06-09 - Prophylactic Irradiation of Tracts in Patients with Malignant Pleural Mesothelioma: A Systematic Review and Meta-Analysis
09:45 - 09:45 | Presenter: Yu Yang Soon
- Abstract
Loading... -
+
P1.06-10 - 18F-FDG PET/CT in Malignant Pleural Mesothelioma: Diagnostic/Prognostic Performance and Correlation with Pathological Results (Now Available)
09:45 - 09:45 | Presenter: Filippo Lococo
- Abstract
Loading... -
+
P1.06-11 - Overlapping Immunophenotypes Between Mesothelioma and Angiosarcoma: Usefulness of Claudin-5 in the Differential Diagnosis
09:45 - 09:45 | Presenter: Yasuhiro Nakashima
- Abstract
Loading... -
+
P1.06-12 - Defects in Homologous Recombination Repair Indicates Susceptibility for Olaparib Treatment in Malignant Pleural Mesothelioma (Now Available)
09:45 - 09:45 | Presenter: Sabrina Borchert
- Abstract
Loading... -
+
P1.06-13 - Treatment Patterns and Outcomes in Advanced Malignant Pleural Mesothelioma: Surveillance, Epidemiology, and End Results Data (Now Available)
09:45 - 09:45 | Presenter: Melinda Daumont
- Abstract
Loading... -
+
P1.06-14 - Posterior Intercostal Lymph Node Positivity as a Prognostic Indicator of Overall Survival in Resectable Malignant Pleural Mesothelioma (Now Available)
09:45 - 09:45 | Presenter: Aneesha Hossain
- Abstract
Loading... -
+
P1.06-15 - Safety of Irradiation Combined with Intracavitary Cisplatin-Fibrin After Lung-Sparing Surgery in a Rat Model of Mesothelioma
09:45 - 09:45 | Author(s): Olivia Lauk
- Abstract
Loading... -
+
P1.06-16 - Molecular Signature in Malignant Pleural Mesothelioma (MPM). Preliminary Data of Rames Study
09:45 - 09:45 | Presenter: Maria Pagano
- Abstract
Loading... -
+
P1.06-17 - Tumor Treating Fields (150 kHz) Combined with Cisplatin or Pemetrexed Inhibits Mesothelioma Cells in Vitro and in Vivo
09:45 - 09:45 | Presenter: Uri Weinberg
- Abstract
Loading... -
+
P1.06-18 - MicroRNA Expression Is Linked to Response of Malignant Pleural Mesothelioma to Cisplatin-Pemetrexed Chemotherapy
09:45 - 09:45 | Author(s): Yan Zhang
- Abstract
Loading... -
+
P1.06-19 - Regional Mesothelioma Multidisciplinary Team Meetings: Perspectives from a UK Cardiothoracic Tertiary Centre (Now Available)
09:45 - 09:45 | Presenter: Kate Slaven
- Abstract
Loading... -
+
P1.06-20 - Malignant Pleural Mesothelioma: Survival Meta-Analysis from 15 Years of a Standard Systemic Therapy
09:45 - 09:45 | Presenter: Joseph Friedberg
- Abstract
Loading... -
+
P1.06-21 - Safety Meta-Analysis of Clinical Trials Delivering Tumor Treating Fields to the Upper Torso
09:45 - 09:45 | Presenter: Uri Weinberg
- Abstract
Loading... -
+
P1.06-22 - Pathologic and Imaging Response Correlations in Patients Treated with Neoadjuvant Chemotherapy for Mesothelioma
09:45 - 09:45 | Presenter: Muneeb Rehman
- Abstract
Loading...
-
+
P1.07 - Nursing and Allied Professionals
- Type: Poster Viewing in the Exhibit Hall
- Track: Nursing and Allied Professionals
- Presentations: 10
- Now Available
- Coordinates: 9/08/2019, 09:45 - 18:00, Exhibit Hall
-
+
P1.07-01 - Lung Cancer Support Groups: Still Relevant in a Digital World?
09:45 - 09:45 | Presenter: Maureen Rigney
- Abstract
Loading... -
+
P1.07-02 - Implementation of a Health and Wellbeing Programme in Conjunction with Pulmonary Rehabiliatation
09:45 - 09:45 | Presenter: Josianne Roberts
- Abstract
Loading... -
+
P1.07-03 - Improving Non-Oncology Provider Knowledge of Unique Immunotherapy Adverse Events (Now Available)
09:45 - 09:45 | Presenter: Enza Esposito Nguyen
- Abstract
Loading... -
+
P1.07-04 - Early Lung Cancer Team Intervention in Emergency Admissions (Now Available)
09:45 - 09:45 | Author(s): Martin Ledson
- Abstract
Loading... -
+
P1.07-05 - Developing a Nursing Triage Tool to Assess Patient Support Needs Through Treatment for Lung Cancer
09:45 - 09:45 | Author(s): Hilary Neal
- Abstract
Loading... -
+
P1.07-06 - Use of the Nutritional Risk Index as Screening for Malnutrition in Patients with Lung Cancer (Now Available)
09:45 - 09:45 | Author(s): Amanda Maria Ferreira
- Abstract
Loading... -
+
P1.07-07 - An Interdisciplinary Collaborative Approach to Discharge Readiness on a Thoracic Surgery Specialty Unit
09:45 - 09:45 | Presenter: Sorah Levy
- Abstract
Loading... -
+
P1.07-08 - Screening for Fear of Cancer Recurrence in Operable Lung Cancer Patients-Scale Validation and Current Status
09:45 - 09:45 | Presenter: Yeur-Hur Lai
- Abstract
Loading... -
+
P1.07-09 - Implementation of a Nursing Program for Cancer Patients Treated with Immunotherapy by an Immunotherapy Nurse Specialist
09:45 - 09:45 | Presenter: Jorgina Serra
- Abstract
Loading... -
+
P1.07-10 - Investigation on Nutritional Status and Quality of Life of Patients with Lung Cancer Treated by Radiotherapy in Different Sexes
09:45 - 09:45 | Presenter: Shu-Ping Xie
- Abstract
Loading... -
+
P1.07-11 - An Evaluation of the Patient’s Experience and Expectations During the Implementation of NHS England, National Optimal Lung Cancer Pathway (Now Available)
09:45 - 09:45 | Presenter: Karen Jane Clayton
- Abstract
Loading... -
+
P1.07-12 - Essential Psychosocial Requirements for Quality Lung Cancer Care
09:45 - 09:45 | Presenter: Csaba Laszlo Degi
- Abstract
Loading... -
+
P1.07-13 - The Application of Intracavitary Electrocardiogram in the Femoral Vein Catheter Tip Location in Chemotherapy Patients with Lung Cancer (Now Available)
09:45 - 09:45 | Presenter: Jinghui Zhang
- Abstract
Loading... -
+
P1.07-14 - Frailty and Treatment Decision Making in Older People with Lung Cancer (Now Available)
09:45 - 09:45 | Presenter: Angela Mary Tod
- Abstract
Loading... -
+
P1.07-15 - Screening for Long Term Ototoxicity in Lung and Upper Aerodigestive Cancer Survivors Treated with Platinum Chemotherapy
09:45 - 09:45 | Presenter: Simranjit Kooner
- Abstract
Loading... -
+
P1.07-16 - Training Program for University Nursing Students to Reduce Lung Cancer Patient Emotional Distress (Now Available)
09:45 - 09:45 | Presenter: Somaya El sayed Abouabdou
- Abstract
Loading... -
+
P1.07-17 - Transfer of Care: Effective Communication to Promote Improved Patient Experience (Now Available)
09:45 - 09:45 | Presenter: Nazanin Nouriany
- Abstract
Loading... -
+
P1.07-18 - The Effect of Lung Cancer on Patient Sexual Functioning: Nursing View (Now Available)
09:45 - 09:45 | Presenter: Somaya El sayed Abouabdou
- Abstract
Loading... -
+
P1.07-19 - Palliative Care Social Workers Multi-Dimensional Roles: A Namibian Perspective
09:45 - 09:45 | Presenter: Rachel J Johanna Freeman
- Abstract
Loading... -
+
P1.07-20 - Evaluation of the Efficacy of Continuing Nursing Education Sessions for Oncology Nurses at Princess Margaret Cancer Centre (Now Available)
09:45 - 09:45 | Presenter: Nazanin Nouriany
- Abstract
Loading...
-
+
P1.09 - Pathology
- Type: Poster Viewing in the Exhibit Hall
- Track: Pathology
- Presentations: 7
- Now Available
- Coordinates: 9/08/2019, 09:45 - 18:00, Exhibit Hall
-
+
P1.09-01 - Immunoprofiling Depends on Molecular Determinants to Predict Metastases and Target Therapy in Non-Small Cell Lung Carcinomas
09:45 - 09:45 | Presenter: Juliana Rugolo-Machado
- Abstract
Loading... -
+
P1.09-02 - Comprehensive Genomic Profiling of Non-Small Cell Lung Cancer in Brazil (GBOT 0118/LACOG 0418) (Now Available)
09:45 - 09:45 | Presenter: Eldsamira Mascarenhas
- Abstract
Loading... -
+
P1.09-03 - Clinicopathological Characteristics for NSCLC Harboring EGFR Exon 20 Insertion
09:45 - 09:45 | Presenter: Kei Morikawa
- Abstract
Loading... -
+
P1.09-04 - Comprehensive Genomic Profiling in a Brazilian Cohort of Lung Cancer Patients: Real-World Impact (Now Available)
09:45 - 09:45 | Presenter: Tiago Costa de Padua
- Abstract
Loading... -
+
P1.09-05 - ALK Testing in Chinese Advanced NSCLC Patients: A National-Wide Multicenter Prospective Real-World Data Study (The RATICAL Study)
09:45 - 09:45 | Presenter: Jianming Ying
- Abstract
Loading... -
+
P1.09-06 - Evaluation of Molecular Testing in a Dutch Cohort of Metastatic Non-Small Cell Lung Cancer Patients from 2017
09:45 - 09:45 | Presenter: Chantal Kuijpers
- Abstract
Loading... -
+
P1.09-07 - The Clinical Utility and Performance of Whole-Exome Sequencing for NSCLC Patient Care: A Comparison to Standard-of-Care
09:45 - 09:45 | Presenter: Kenneth John O’Byrne
- Abstract
Loading... -
+
P1.09-08 - Registration of Pre-Operative Lung Cancer PET/CT Scans with Post-Operative Histopathology Maps
09:45 - 09:45 | Presenter: Gabriel Reines March
- Abstract
Loading... -
+
P1.09-09 - Model to Predict Small Lymph Nodes Metastasis in Non-Small Cell Lung Cancer (Now Available)
09:45 - 09:45 | Presenter: Jiancheng Li
- Abstract
Loading... -
+
P1.09-10 - Molecular Immunocytochemistry in Various NSCLC Samples Prepared as Non-Cell Block Cytology (Now Available)
09:45 - 09:45 | Presenter: Silvana Smojver-Ježek
- Abstract
Loading... -
+
P1.09-11 - Influences of Sampling Method to Morphological Feature Measurement of Lung Cancer Cell
09:45 - 09:45 | Presenter: Tomoharu Kiyuna
- Abstract
Loading... -
+
P1.09-12 - In-Situ Hybridization Visual Scoring of Epigenetic Imprinting Genes Improves Early Diagnosis and Grading of Lung Cancers (Now Available)
09:45 - 09:45 | Presenter: Rex C Yung
- Abstract
Loading... -
+
P1.09-13 - Prognostic Value of TMPRSS4 Expression and Its Role as Diagnostic Biomarker by Liquid Biopsy in Early Stage NSCLC
09:45 - 09:45 | Presenter: Francisco Exposito
- Abstract
Loading... -
+
P1.09-14 - Comparison Between Liquid Biopsy and Conventional Tissue Biopsy in EGFR Genotyping of Non-Small Cell Lung Cancer
09:45 - 09:45 | Presenter: Sang Hoon Lee
- Abstract
Loading... -
+
P1.09-15 - Hybrid Organoid Reveals That Podoplanin-Positive Cancer-Associated Fibroblasts Enhance Proliferation of Lung Cancer Cell
09:45 - 09:45 | Presenter: Hiroshi Nakamura
- Abstract
Loading... -
+
P1.09-16 - Tumor Proliferation Is Associated with the Tumor Immunological Status: A Study on NSCLC Using Multiplex Immunofluorescence
09:45 - 09:45 | Presenter: Andreas Spitzmüller
- Abstract
Loading... -
+
P1.09-17 - In the Minimally Invasive Era, What Is the Role of Intra-Operative Frozen Section Prior to Lobectomy: A Single Institution Perspective
09:45 - 09:45 | Presenter: Ashok Kar
- Abstract
Loading... -
+
P1.09-18 - Small-Sized Spread Through Air Spaces (STAS) in Resected Pulmonary Adenocarcinoma: Is It Necessary to Record It as a Prognostic Factor?
09:45 - 09:45 | Presenter: Akihiko Yoshizawa
- Abstract
Loading... -
+
P1.09-19 - High-Throughput Next Generation Sequencing of Treatment-Naïve Non-Squamous NSCLC: The Singapore National Lung Profiling Study
09:45 - 09:45 | Presenter: Aaron C Tan
- Abstract
Loading... -
+
P1.09-20 - Significance of Maximal Diameter Measurement in Small-Sized Adenocarcinomas
09:45 - 09:45 | Presenter: Hironori Ninomiya
- Abstract
Loading... -
+
P1.09-21 - Tumor Responses Based on Tumor Growth Rate During PD-1 Inhibitor Therapy in Advanced Non-Small-Cell Lung Cancer Patients
09:45 - 09:45 | Author(s): Deirdre MHJ Ten Berge
- Abstract
Loading... -
+
P1.09-22 - Programmed Death Ligand-1 Expression in Non-Small Cell Lung Cancer in Mexican Population and Correlation with Clinicopathologic Features
09:45 - 09:45 | Author(s): Leticia Bornstein
- Abstract
Loading... -
+
P1.09-23 - A33 and SATB2 Immunohistochemistry for Differentiating Metastatic Colorectal Carcinoma from Pulmonary Enteric Adenocarcinoma
09:45 - 09:45 | Presenter: Likun Hou
- Abstract
Loading... -
+
P1.09-24 - Tumor Necrosis Correlates with PD-L1 and PD-1 Expression in Lung Adenocarcinoma
09:45 - 09:45 | Presenter: Judit Moldvay
- Abstract
Loading... -
+
P1.09-25 - The Use of In-Situ RNA Analysis in the Detection of Metastatic HPV Mediated Squamous Cell Carcinoma to the Lung with p16 Correlation (Now Available)
09:45 - 09:45 | Presenter: Roula Katerji
- Abstract
Loading... -
+
P1.09-26 - Prevalence of PD-L1 Expression Rates in Different NSCLC Specimens
09:45 - 09:45 | Author(s): Mikaela Holmes
- Abstract
Loading... -
+
P1.09-27 - Interobserver Variation in the Cytological Diagnosis of Pulmonary Adenocarcinoma Presenting with Ground-Glass Opacity Nodules
09:45 - 09:45 | Presenter: Heae Surng Park
- Abstract
Loading... -
+
P1.09-28 - A Significant Discordance Between PANAMutyper™ and Targeted Deep Sequencing for Detecting EGFR Mutation in NSCLC
09:45 - 09:45 | Presenter: Jeonghyo Lee
- Abstract
Loading... -
+
P1.09-30 - Molecular Characterization of Preinvasive and Invasive Lesions in Multifocal Pulmonary Adenocarcinomas
09:45 - 09:45 | Presenter: Hsiang-Ling Ho
- Abstract
Loading... -
+
P1.09-31 - Clinicopathological Features and Genomic Profiling of Pulmonary Blastoma with High-Grade Fetal Adenocarcinoma Component
09:45 - 09:45 | Presenter: Jikai Zhao
- Abstract
Loading... -
+
P1.09-32 - Concurrent Genomic Alterations in ALK-Rearranged Non-Small Cell Lung Cancer Patients
09:45 - 09:45 | Presenter: Sergi Clavé
- Abstract
Loading... -
+
P1.09-33 - More than 40% of Locally Advanced or Metastatic NSCLC Patients Without EGFR/ALK Alterations Have PD-L1 TPS >= 1% in China (Now Available)
09:45 - 09:45 | Author(s): Suqin Ben
- Abstract
Loading...
-
+
P1.10 - Prevention and Tobacco Control
- Type: Poster Viewing in the Exhibit Hall
- Track: Prevention and Tobacco Control
- Presentations: 3
- Now Available
- Coordinates: 9/08/2019, 09:45 - 18:00, Exhibit Hall
-
+
P1.10-01 - Patterns of Birth Cohort-Specific Smoking Histories by Race and Ethnicity in the US, 1965-2017
09:45 - 09:45 | Presenter: Rafael Meza
- Abstract
Loading... -
+
P1.10-02 - Role Models and Lung Cancer Awareness: Does It Change the Mind-Set and Perception of General Population?
09:45 - 09:45 | Presenter: Deepak Saini
- Abstract
Loading... -
+
P1.10-03 - Gut Microbiota and Lung Cancer: A Mendelian Randomisation Study (Now Available)
09:45 - 09:45 | Presenter: Huaqiang Zhou
- Abstract
Loading... -
+
P1.10-04 - Lung Cancer in Patients with HIV Disease - Unique Clinical and Biomarker Features Impacting Lung Cancer Screening and Management
09:45 - 09:45 | Author(s): Shirin Attarian
- Abstract
Loading... -
+
P1.10-05 - Tobacco Retail Availability and Tobacco Cessation Among Lung Cancer Survivors
09:45 - 09:45 | Author(s): Lawson Eng
- Abstract
Loading... -
+
P1.10-06 - Pathological Characterization of Radon-Induced Lung Cancer in Rats
09:45 - 09:45 | Presenter: Laura Mezquita
- Abstract
Loading... -
+
P1.10-07 - Characteristics of Current and Former Smokers Who Acknowledge Their Risk of Lung Cancer: Results from the EDIFICE6 Survey (Now Available)
09:45 - 09:45 | Author(s): Sébastien Couraud
- Abstract
Loading... -
+
P1.10-08 - The Usefulness of Inpatient Smoking Cessation Program at Single Cancer Center
09:45 - 09:45 | Presenter: In-Jae Oh
- Abstract
Loading... -
+
P1.10-09 - Cessation Rates of an Expanded Pharmacy-Driven Smoking Cessation Program
09:45 - 09:45 | Author(s): Zirah Acosta
- Abstract
Loading... -
+
P1.10-10 - Social Vulnerability and Survival in Lung Cancer in Emerging Country (Now Available)
09:45 - 09:45 | Author(s): Priscila Berenice Costa
- Abstract
Loading... -
+
P1.10-11 - Examination of Lifestyle Factors and Associations with Genetic Mutations in Lung Cancer Cases
09:45 - 09:45 | Presenter: Marisa Bittoni
- Abstract
Loading...
-
+
P1.11 - Screening and Early Detection
- Type: Poster Viewing in the Exhibit Hall
- Track: Screening and Early Detection
- Presentations: 8
- Now Available
- Coordinates: 9/08/2019, 09:45 - 18:00, Exhibit Hall
-
+
P1.11-01 - The Implementation of the Lung-RADS ™ in Pilot Silesian Study with LDCT - An Opportunity for Better Control of Overdiagnosis
09:45 - 09:45 | Presenter: Ewa Wachula
- Abstract
Loading... -
+
P1.11-02 - Acceleration of Lung Cancer Diagnosis: Utility Study for AI-Based Stratification of Pulmonary Nodules
09:45 - 09:45 | Author(s): Lyndsey C Pickup
- Abstract
Loading... -
+
P1.11-03 - Disparities and National Lung Cancer Screening Guidelines in the U.S. Population
09:45 - 09:45 | Presenter: Summer S Han
- Abstract
Loading... -
+
P1.11-04 - Utilizing DNA Repair Activity Biomarkers for Lung Cancer Risk Assessment and Early Detection
09:45 - 09:45 | Presenter: Tamar Paz-Elizur
- Abstract
Loading... -
+
P1.11-05 - Genetic Architecture of Lung Cancer Using Machine-Learning Approaches in Genome-Wide Association Studies
09:45 - 09:45 | Presenter: Jinyoung Byun
- Abstract
Loading... -
+
P1.11-06 - Expanding Criteria for Lung Cancer Screening Reduces Gender Disparity
09:45 - 09:45 | Presenter: Mary M. Pasquinelli
- Abstract
Loading... -
+
P1.11-07 - CfDNA from Bronchoalveolar Lavage Fluid for the Identification of Solid Pulmonary Nodules: A New Medium of Liquid Biopsy (Now Available)
09:45 - 09:45 | Presenter: Junhong Jiang
- Abstract
Loading... -
+
P1.11-08 - Are Risk Prediction Models Superior Over Standard Criteria for Lung Cancer Screening in Europe? Macroscale Simulation on Large Polish Cohort
09:45 - 09:45 | Presenter: Marcin Ostrowski
- Abstract
Loading... -
+
P1.11-09 - Risk of Second Primary Malignancy After Non-Small-Cell Lung Cancer: A Competing Risk Nomogram Based on the SEER Database
09:45 - 09:45 | Author(s): Huaqiang Zhou
- Abstract
Loading... -
+
P1.11-10 - Serum MicroRNA Biomarkers for Screening of Resectable Lung Cancer
09:45 - 09:45 | Presenter: Keisuke Asakura
- Abstract
Loading... -
+
P1.11-11 - Initial Discovery of Exhaled Small Polar Energetics-Related Metabolites by GC-MS for Lung Cancer Risk Assessment
09:45 - 09:45 | Presenter: Simon D Spivack
- Abstract
Loading... -
+
P1.11-12 - Genetic Landscape and Immune Microenvironment Features in Recurrence in Stage IA of Lung Adenocarcinoma
09:45 - 09:45 | Presenter: Lu Yang
- Abstract
Loading... -
+
P1.11-13 - Mass Spectrometry Proteomics Analysis Discovers Biomarkers in Serum Months to Years Before Non-Small Cell Lung Cancer: The HUNT Study
09:45 - 09:45 | Presenter: Olav Toai Duc Nguyen
- Abstract
Loading... -
+
P1.11-14 - SGLT2 Is a Diagnostic and Therapeutic Target for Early-Stage Lung Adenocarcinoma
09:45 - 09:45 | Author(s): Brendon Villegas
- Abstract
Loading... -
+
P1.11-15 - Feasibility of a Lung Health Clinic for Early Lung Cancer Identification in High-Risk Individuals in South-East London
09:45 - 09:45 | Author(s): Arjun Nair
- Abstract
Loading... -
+
P1.11-16 - Squamous Cell Lung Cancer Risk Is Associated with Rare, Pathogenic Germline Variants in BRCA2 and Fanconi Anemia Genes
09:45 - 09:45 | Author(s): Myvizhi Esai Selvan
- Abstract
Loading... -
+
P1.11-17 - Osteoporosis, Coronary Artery Calcification, and COPD in a Lung Cancer Screening Cohort
09:45 - 09:45 | Presenter: James Finigan
- Abstract
Loading... -
+
P1.11-18 - The Results of Mandatory Smoking Cessation Intervention in a Population-Based Lung Cancer Screening Trial
09:45 - 09:45 | Presenter: Eunju Lee
- Abstract
Loading... -
+
P1.11-19 - Trial in Progress: Cancer Screening Study With or Without Low Dose Lung CT to Validate a Multi-Cancer Early Detection Blood Test
09:45 - 09:45 | Presenter: Sam Janes
- Abstract
Loading... -
+
P1.11-20 - Identification of a Thirteen-Gene Prognostic Signature for Lung Adenocarcinoma (Now Available)
09:45 - 09:45 | Author(s): Yuanyong Wang
- Abstract
Loading... -
+
P1.11-21 - Liverpool Health Lung Project: Significant Incidental Findings in a Smoker-Predominant Cohort (Now Available)
09:45 - 09:45 | Presenter: Martin Ledson
- Abstract
Loading... -
+
P1.11-22 - Lung Cancer Growth: Impact of Different Assumptions
09:45 - 09:45 | Author(s): Maham Siddique
- Abstract
Loading... -
+
P1.11-23 - The Impact of the Family History of Different Cancers on Lung Cancer
09:45 - 09:45 | Presenter: Jianfu Li
- Abstract
Loading... -
+
P1.11-24 - Implementation of an Organized Lung Cancer Screening Program in Korea (Now Available)
09:45 - 09:45 | Presenter: Yeol Kim
- Abstract
Loading... -
+
P1.11-25 - Adjustment for Lead-Time Bias and Over-Diagnosis in Lung Cancer Screening
09:45 - 09:45 | Presenter: Szu-Chun Yang
- Abstract
Loading... -
+
P1.11-26 - The Epidemiology of Ground Glass Opacity (GGO) Lung Adenocarcinoma: A Network Based Cumulative Meta-Analysis
09:45 - 09:45 | Presenter: Xiongfei Li
- Abstract
Loading... -
+
P1.11-27 - Computed Tomography Screening for Early Lung Cancer, COPD and Cardiovascular Disease in Shanghai: Rationale and Design of a Population-Based Comparative Study
09:45 - 09:45 | Presenter: Yihui Du
- Abstract
Loading... -
+
P1.11-28 - Lung Cancer: Susceptibility and Survival Differences for Women and Men
09:45 - 09:45 | Author(s): Rowena Yip
- Abstract
Loading... -
+
P1.11-29 - Relationship Between Lung Cancer Screening Centers in the United States and High-Risk Individuals (Now Available)
09:45 - 09:45 | Presenter: Candice Leigh Wilshire
- Abstract
Loading... -
+
P1.11-30 - Very Rapid Growth of Small Pulmonary Nodules Predicts Benignity
09:45 - 09:45 | Presenter: Joseph Barnett
- Abstract
Loading... -
+
P1.11-31 - Understanding Referral Patterns in a Lung Cancer Screening Program (Now Available)
09:45 - 09:45 | Presenter: Diane Nabil Haddad
- Abstract
Loading... -
+
P1.11-32 - The UKLS Nodule Risk Model (UKLS-NRM): Utilising Nodule Volumetry
09:45 - 09:45 | Author(s): Michael W. Marcus
- Abstract
Loading... -
+
P1.11-33 - Prognostic Value of Symptoms at Lung Cancer Diagnosis: A Two-Year Observational Study (Now Available)
09:45 - 09:45 | Presenter: Dinora Polanco
- Abstract
Loading... -
+
P1.11-34 - The Liverpool Healthy Lung Project – Championing the Importance of Lung Health (Now Available)
09:45 - 09:45 | Presenter: Martin Ledson
- Abstract
Loading... -
+
P1.11-35 - Comparison of Lung Cancer Screening Trials from East Asia; South Korea, Japan, and Taiwan
09:45 - 09:45 | Presenter: Sang Won Shin
- Abstract
Loading... -
+
P1.11-36 - A Simple Tool to Prioritize US Ever-Smokers for CT Screening Eligibility Assessment
09:45 - 09:45 | Presenter: Hilary Robbins
- Abstract
Loading... -
+
P1.11-37 - Face Your Fear Awareness Campaign
09:45 - 09:45 | Presenter: Lorraine Shona Dallas
- Abstract
Loading... -
+
P1.11-38 - Frequency and Prognostic Impact of Concomitant Mutations in KRAS and TP53 or STK11 in Brazilian Lung Adenocarcinoma Patients
09:45 - 09:45 | Author(s): Vanessa Karen De Sa
- Abstract
Loading... -
+
P1.11-39 - Low-Dose CT Lung Screening: Data Analysis of Lung Cancer Patients with Above 40 Years Old
09:45 - 09:45 | Presenter: Yujing Jin
- Abstract
Loading... -
+
P1.11-40 - Systematic Development and Multi-Cohort Validation of a Serum miRNA Biomarker Panel for Detection of Early Stage Non-Small Cell Lung Cancer
09:45 - 09:45 | Presenter: Lihan Zhou
- Abstract
Loading...
-
+
P1.12 - Small Cell Lung Cancer/NET
- Type: Poster Viewing in the Exhibit Hall
- Track: Small Cell Lung Cancer/NET
- Presentations: 7
- Now Available
- Coordinates: 9/08/2019, 09:45 - 18:00, Exhibit Hall
-
+
P1.12-01 - CD81-HOTTIP Regulating Loop Enhances Myc-Mediated Chemoresistance in Small Cell Lung Cancer via ERK Signaling Pathway
09:45 - 09:45 | Presenter: Linlang Guo
- Abstract
Loading... -
+
P1.12-02 - Nationwide Assessment of the Role of Adjuvant Systemic Therapy in High-Risk Lung Carcinoids (Now Available)
09:45 - 09:45 | Author(s): Mohamed K Kamel
- Abstract
Loading... -
+
P1.12-03 - Antitumor Activity of Single Agent Lurbinectedin in Patients with Relapsed SCLC Occurring ≥30 Days After Last Platinum Dose
09:45 - 09:45 | Presenter: Jose Manuel Trigo Perez
- Abstract
Loading... -
+
P1.12-04 - A Phase I Study of the 177Lu-DOTA0-Tyr3-Octreotate in Combination with Nivolumab in Patients with Extensive-Stage Small Cell Lung Cancer
09:45 - 09:45 | Presenter: Chul Kim
- Abstract
Loading... -
+
P1.12-05 - Microenvironment Characterization of Small Cell Lung Cancer Xenografts Implanted in Hematopoietic Humanized Mice
09:45 - 09:45 | Presenter: Hui Yu
- Abstract
Loading... -
+
P1.12-06 - Ozone-Primed Neutrophils Promote Early Steps of Tumor Cell Metastasis to Lungs by Enhancing Their NETs Production (Now Available)
09:45 - 09:45 | Author(s): Natache Rocks
- Abstract
Loading... -
+
P1.12-07 - Near Infrared Photoimmunotherapy Targeting DLL3 Against Small Cell Lung Cancer
09:45 - 09:45 | Presenter: Yoshitaka Isobe
- Abstract
Loading... -
+
P1.12-08 - The Impact of Patient Age and Socioeconomic Factors on Clinical Outcomes in Small Cell Lung Cancer (SCLC): A National Study (Now Available)
09:45 - 09:45 | Presenter: Ruqin Chen
- Abstract
Loading... -
+
P1.12-09 - RNA Sequencing in Small Cell Lung Carcinoma Reveals Change in Neuroendocrine Pattern in Primary Tumor Versus Lymph Node Metastases
09:45 - 09:45 | Presenter: Zoltán Lohinai
- Abstract
Loading... -
+
P1.12-10 - The Genomic Profiles of Small Cell Lung Cancer in East Asian (Now Available)
09:45 - 09:45 | Author(s): Zheng-bo Song
- Abstract
Loading... -
+
P1.12-11 - Exploring Sex Differences in Small Cell Lung Cancer: Is This a Hormonal Issue?
09:45 - 09:45 | Presenter: Narjust Duma
- Abstract
Loading... -
+
P1.12-12 - Factors Affecting the Risk of Brain Metastasis in Limited-Stage Small Cell Lung Cancer After Prophylactic Cranial Irradiation
09:45 - 09:45 | Presenter: Mengyuan Chen
- Abstract
Loading... -
+
P1.12-13 - The Past, Present, and Future of SCLC and NSCLC Incidence, Mortality, and Prevalence in Denmark During 2006 Through 2030
09:45 - 09:45 | Presenter: Anders Green
- Abstract
Loading... -
+
P1.12-14 - Phase II Trial of Apatinib Plus Chemotherapy for Second-Line and Above Treatment of Advanced SCLC: Focus on Efficacy and Safety (Now Available)
09:45 - 09:45 | Presenter: Kewei Ma
- Abstract
Loading... -
+
P1.12-15 - PET Imaging of [18F]PARP Inhibitor as a Pharmacodynamic Biomarker of Talazoparib in Small Cell Lung Cancer PDXs
09:45 - 09:45 | Presenter: Benjamin Lok
- Abstract
Loading... -
+
P1.12-16 - LMW Heparin Adherence and Effects on Survival Within a Randomized Phase III Lung Cancer Trial (RASTEN)
09:45 - 09:45 | Presenter: Emelie Gezelius
- Abstract
Loading... -
+
P1.12-17 - Association Between the Pharmacokinetics and Clinical Outcome of Amrubicin Treatment
09:45 - 09:45 | Presenter: Satoshi Fukuda
- Abstract
Loading... -
+
P1.12-18 - Nonclinical Safety Assessment of AMG 757, a DLL3 Bispecific T Cell Engager, in the Cynomolgus Monkey
09:45 - 09:45 | Presenter: Edward K Lobenhofer
- Abstract
Loading... -
+
P1.12-19 - Identification and Potential Application of Human Blood Exosomal RNA in Small Cell Lung Cancer (Now Available)
09:45 - 09:45 | Author(s): Chang Liu
- Abstract
Loading... -
+
P1.12-20 - Surgical Resection Versus Stereotactic Body Radiation Therapy for T1-2 N0 Typical Bronchopulmonary Carcinoid Tumors
09:45 - 09:45 | Presenter: Rodney Ervin Wegner
- Abstract
Loading... -
+
P1.12-21 - Impact of Treatment Modality on Long-Term Survival of Small-Cell Lung Cancer with IA Stage: A Cohort Study of the US SEER Database
09:45 - 09:45 | Presenter: Kunshou Zhu
- Abstract
Loading... -
+
P1.12-22 - A Phase 1b/2 Study of Niraparib Plus Temozolomide Versus Standard Care as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer Patients
09:45 - 09:45 | Presenter: Amy Lauren Cummings
- Abstract
Loading... -
+
P1.12-23 - DLL3 Is a Predictive Marker of Sensitivity to Adjuvant Chemotherapy for High-Grade Neuroendocrine Tumors
09:45 - 09:45 | Presenter: Hiroyuki Ogawa
- Abstract
Loading... -
+
P1.12-24 - Comparison of Four Prognostic Scores for Patients with Brain Metastases from Small-Cell Lung Cancer (Now Available)
09:45 - 09:45 | Presenter: Lei Zhao
- Abstract
Loading...